Drugs for preventing or treating neurodegenerative diseases

By combining rifampicin with resveratrol and nasal administration, the side effects and poor effects of existing therapeutic drugs were solved, and long-term prevention and treatment of neurodegenerative diseases were achieved, which significantly improved the therapeutic effect.

CN113260357BActive Publication Date: 2024-11-15MEDILABO RFP INC
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
CN202080008071.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-01-09
Filing Date
2020-01-09
Publication Date
2024-11-15
Estimated Expiration
2040-01-09

AI Technical Summary

Technical Problem

Existing therapeutic drugs for Alzheimer's disease and other neurodegenerative diseases fail due to side effects or insignificant effects, and it is difficult to administer preventively before the onset of the disease, resulting in poor treatment effect.

Method used

Combining rifampin with resveratrol, by nasal administration, reduce side effects, and long-term administration in low dosages to prevent or treat neurodegenerative diseases, use the antibiotic properties of rifampin to inhibit protein oligomer formation, and enhance the effect through resveratrol.

Benefits of technology

It significantly reduces side effects, achieves long-term prevention or treatment of neurodegenerative diseases, improves cognitive function, and enhances the therapeutic effect on diseases such as Alzheimer's disease through the use of combined drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113260357B_ABST
    Figure CN113260357B_ABST
Patent Text Reader

Abstract

The object of the present invention is to provide a rifampicin administration technology that can reduce side effects and can be administered for a long time. A nasal drug for the prevention or treatment of neurodegenerative diseases, comprising: rifampicins and resveratrols, wherein the rifampicins are selected from the group consisting of rifampicin, its derivatives and their salts, and the resveratrols are selected from the group consisting of resveratrol and its derivatives. The nasal drug has reduced side effects and can be administered for a long time.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a pharmaceutical product which is useful for preventing or treating a neurodegenerative disease and has suppressed side effects. Background Art

[0002] Neurodegenerative diseases are diseases that occur in the central nervous system, and their pathological characteristics include a decrease in a specific population of nerve cells and accumulation of fibrous substances that frequently appear inside and outside nerve cells.

[0003] Neurodegenerative diseases include Alzheimer's disease (AD) with accumulation of β-amyloid protein (Aβ), tauopathy with accumulation of Tau, and synucleinopathy with accumulation of α-synuclein. Tauopathy includes frontotemporal lobar degeneration (FTLD) such as Pick's disease, corticobasal degeneration (CBD), and progressive supranuclear palsy (PSP), and sometimes AD is also included because Tau accumulates in addition to Aβ. FTLD is called frontotemporal lobar dementia (FTD) when focusing on dementia as a clinical symptom. Synucleinopathy includes dementia with Lewy bodies (DLB), Parkinson's disease (PD), and multiple system atrophy (MSA). It is believed that neurodegenerative diseases are caused by the formation of oligomers of these proteins in the brain, which damages the function of nerve cells and causes the disease to occur. Based on this concept, drugs that have the effects of inhibiting the production of these proteins, inhibiting the formation of oligomers, and removing aggregated proteins from the brain are being developed as therapeutic drugs for neurodegenerative diseases.

[0004] For example, for AD, inhibitors of enzymes related to the production of Aβ (β-secretase or γ-secretase), Aβ vaccines that remove Aβ from the brain, Aβ antibodies, etc. have been developed and put into clinical trials. However, most of them have failed in clinical trials so far due to unexpected side effects or failure to show the expected efficacy.

[0005] On the other hand, rifampicin, which is well known as an antibiotic, has been used as an oral drug due to its antibacterial action. Furthermore, rifampicin is also known to have a free radical scavenging action, and one of its actions is reported to be involved in the inhibition of Aβ aggregation reaction (Non-Patent Document 1).

[0006] In addition, resveratrol is a kind of polyphenol contained in the peel of grape, red wine, the endothelium of peanut, etc., and is reported to have the effects of anti-cancer, anti-atherosclerosis, anti-obesity, anti-diabetes, anti-inflammatory, etc. (non-patent literature 2). In addition, it is also reported that resveratrol has the effect of reducing the oxidative stress of neuron-like cells, specifically, it has been confirmed that resveratrol induces the phosphorylation of mitogen (division-promoting factor) activated protein (MAP) kinase in differentiated and undifferentiated human neuroblastoma SH-SY5Y (non-patent literature 3). On the other hand, although the effect of resveratrol on Alzheimer's disease is expected, it is actually reported that 119 people with mild and moderate Alzheimer's disease were randomly divided into two groups, and in a 52-week verification in which one group took 500 mg of resveratrol and the other group took a placebo, even if a dosing plan of increasing resveratrol by 500 mg every 13 weeks and finally increasing it to 1000 mg twice a day was implemented, it was impossible to confirm that the group administered with resveratrol had effectiveness relative to the group administered with placebo (non-patent document 4). Furthermore, on the other hand, as side effects of resveratrol when taken at high doses or for a long time, nausea, diarrhea, weight loss (non-patent document 5), abdominal pain (non-patent document 4), bladder disorders (non-patent document 6), and renal disorders (non-patent document 7) etc. were reported.

[0007] Prior art literature

[0008] Non-patent literature

[0009] Non-patent literature 1: Tomiyama, T. et al., "Inhibition of amyloid beta protein aggregation and neurotoxicity by rifampicin. Its possible function as a hydroxyl radical scavenger.", J Biol Chem, 1996, Vol. 271, p. 6839-6844

[0010] Non-patent document 2: Yu W. et al., "Cellular and molecular effects of resveratrol in health and disease", J Cell Biochem, 2012, 113, p.752-759

[0011] Non-patent document 3: Tredici G et al., "Resveratrol, map kinases and neuronal cells: might wine be a neuroprotectant?" Drug Exp Clin Res, 1999, 25, p.99-103

[0012] Non-patent document 4: R. Scott Turner et al., “A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease”, 2015, American Academy of Neurology, DOI: 10.1212 / WNL.0000000000002035

[0013] Non-patent document 5: Brown VA. et al., "Repeat dose study of the cancerchemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis", CancerRes, 2010, 70, p.9003-9011

[0014] Non-patent document 6: Edwards JA et al., "Safety of resveratrol with examples for high purity, trans-resveratrol, resVida ((R))", Ann NY Acad Sci, 2011, 1215, p.131-137

[0015] Non-patent document 7: Popat R et al., "A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma", Br J Haematol, 2013, 160, p.714-717 Summary of the invention

[0016] Problems to be solved by the invention

[0017] It is believed that if the problem of side effects is put aside, the reason for the failure of Aβ target drugs (Aβ production enzyme inhibitors, Aβ vaccines, Aβ antibodies, etc.) in clinical trials targeting AD is that the administration period is too late. In other words, it is believed that it is meaningless if Aβ cannot be removed before the onset of dementia when nerve cells begin to die. Therefore, the role of Aβ target drugs should not be treatment but prevention. In addition, it is reported that even with the Tau aggregation inhibitor that was the first to enter clinical trials among Tau target drugs, no improvement in cognitive function was seen in clinical trials targeting AD. As you can imagine, this result also shows that even for Tau target drugs, it is too late to administer the drug after the onset of the disease.

[0018] However, most of the therapeutic drugs currently under development are not developed with preventive administration as a premise, and there are problems in terms of cost, side effects, administration method, etc. On the other hand, since the onset time of neurodegenerative diseases is unclear when administering drugs to prevent them, a considerable period of administration must be assumed.

[0019] On the other hand, the present inventors have found that rifampicin inhibits the formation of oligomers of Aβ, Tau, and α-synuclein in vitro, and when orally administered to model mice of AD with Aβ accumulation and model mice of FTD with Tau accumulation, the accumulation of these protein oligomers in the brain is inhibited, and the cognitive function of the mice is restored. Therefore, the present inventors have studied the use of this action of rifampicin to reposition rifampicin, which has been used as an antibiotic, as a neurodegenerative disease preventive drug and put it into practical use.

[0020] However, as a result of the above research, it was found that the side effects such as liver damage or drug interactions caused by rifampicin are serious in subjects with neurodegenerative diseases, and therefore, the long-term use of rifampicin as a preventive drug is impossible. That is, the problem of side effects caused by rifampicin is significant in subjects with neurodegenerative diseases. Drug interactions here refer to the phenomenon that the effects of other drugs taken at the same time are weakened due to the induction of cytochrome P450 (CYP) and P-glycoprotein related to drug metabolism in hepatocytes by rifampicin.

[0021] Therefore, a first object of the present invention is to provide a formulation of rifampicin that can reduce side effects and can be administered for a long period of time.

[0022] In addition, with respect to resveratrol, the above dosage is not actually confirmed for the effect on Alzheimer's. In the case of expecting the effect of resveratrol on Alzheimer's to be manifested, it is considered to carry out administration with a higher dosage and a longer period, but the risk of side effects such as nausea, diarrhea, weight loss, abdominal pain, bladder disorders, and kidney disorders reported in the high dosage and / or long-term intake of resveratrol is worrying. Therefore, it is believed that according to the reports so far, with respect to resveratrol, it is impossible to administer or take in for a long time while ensuring the effective dose for neurodegenerative diseases such as Alzheimer's.

[0023] Therefore, a second object of the present invention is to provide a preventive or therapeutic drug for neurodegenerative diseases that can be administered over a long period of time, and a food for improving brain function that can be ingested over a long period of time.

[0024] Technical solutions to solve problems

[0025] The present inventors have found that by combining resveratrol with rifampicin, a surprising side effect reduction effect is observed, and long-term administration is possible. In addition, the present inventors unexpectedly found that resveratrol can reduce Aβ oligomers even at very low doses, and found that long-term administration or ingestion at very low doses can improve cognitive function. The present invention is completed by further repeated studies based on the above findings.

[0026] That is, the present invention provides the inventions disclosed in the following aspects.

[0027] Item 1. A preventive or therapeutic agent for a neurodegenerative disease, which is a combination of a rifampicin selected from the group consisting of rifampicin, its derivatives and salts thereof, and a resveratrol selected from the group consisting of resveratrol and its derivatives.

[0028] Item 2. The preventive or therapeutic agent according to Item 1, comprising 1 / 500 to 500 parts by weight of the resveratrol compound based on 1 part by weight of the rifampicin compound.

[0029] Item 3. The preventive or therapeutic agent according to Item 1 or 2, wherein the dosage of the rifampicin is 3.75 mg / kg·day or less.

[0030] Item 4. The preventive or therapeutic agent according to any one of Items 1 to 3, wherein the dosage of the rifampicin is 0.001 to 1.5 mg / kg·day.

[0031] Item 5. The preventive or therapeutic agent according to any one of Items 1 to 4, wherein the dosage of the resveratrol is 3.75 mg / kg·day or less.

[0032] Item 6. The preventive or therapeutic agent according to any one of Items 1 to 5, wherein the dosage of the resveratrol is 0.001 to 2.5 mg / kg·day.

[0033] Item 7. The preventive or therapeutic drug according to any one of Items 1 to 6, wherein the preventive or therapeutic drug is for nasal administration.

[0034] Item 8. The preventive or therapeutic drug according to any one of Items 1 to 7, wherein the preventive or therapeutic drug is used for the prevention or treatment of dementia.

[0035] Item 9. The preventive or therapeutic drug according to any one of Items 1 to 8, wherein the preventive or therapeutic drug is a combination preparation of the rifampicins and the resveratrols.

[0036] Item 10. The preventive or therapeutic drug according to any one of Items 1 to 8, wherein the preventive or therapeutic drug is a kit comprising a drug containing the rifampicin and a drug containing the resveratrol.

[0037] Item 11. A preventive or therapeutic agent for neurodegenerative diseases for nasal administration, comprising a resveratrol selected from the group consisting of resveratrol and derivatives thereof, wherein the dosage of the resveratrol is 0.28 mg / kg·day or less.

[0038] Item 12. The preventive or therapeutic drug according to Item 11, wherein the preventive or therapeutic drug is used for the prevention or treatment of dementia.

[0039] Item 13. The preventive or therapeutic agent according to Item 11 or 12, wherein the administration period is 1 month or longer.

[0040] Item 14. A food for improving brain function, comprising resveratrols selected from the group consisting of resveratrol and derivatives thereof, wherein the intake of the resveratrols is 3.75 mg / kg·day or less.

[0041] Item 15. Use of rifampics and resveratrols for producing a pharmaceutical for preventing or treating a neurodegenerative disease, wherein the rifampics are selected from the group consisting of rifampicin, its derivatives and salts thereof, and the resveratrols are selected from the group consisting of resveratrol and its derivatives.

[0042] Item 16. A method for treating a neurodegenerative disease, comprising the step of administering to a patient suffering from a neurodegenerative disease an effective amount of a rifampicin selected from the group consisting of rifampicin, derivatives thereof and salts thereof, and a resveratrol selected from the group consisting of resveratrol and derivatives thereof.

[0043] Item 17. A method for preventing a neurodegenerative disease, comprising the step of administering an effective amount of a rifampicin selected from the group consisting of rifampicin, its derivatives and salts thereof, and a resveratrol selected from the group consisting of resveratrol and its derivatives to a non-patient with a high risk of developing the neurodegenerative disease.

[0044] Item 18. Use of resveratrols for producing a nasal pharmaceutical for the prevention or treatment of a neurodegenerative disease, the resveratrols being selected from the group consisting of resveratrol and derivatives thereof.

[0045] Item 19. A method for treating a neurodegenerative disease, comprising the step of nasally administering 0.28 mg / kg·day or less of a resveratrol selected from the group consisting of resveratrol and derivatives thereof to a patient with the neurodegenerative disease.

[0046] Item 20. The method according to Item 19, wherein the administration period is 1 month or longer.

[0047] Item 21. A method for preventing a neurodegenerative disease, comprising the step of nasally administering 0.28 mg / kg·day or less of a resveratrol selected from the group consisting of resveratrol and derivatives thereof to a non-patient at high risk of developing the neurodegenerative disease.

[0048] Item 22. The method according to Item 21, wherein the administration period is 1 month or longer.

[0049] Item 23. A method for improving brain function, comprising the step of orally ingesting 3.75 mg / kg·day or less of a resveratrol selected from the group consisting of resveratrol and derivatives thereof.

[0050] Effects of the Invention

[0051] According to the preventive or therapeutic drug of the present invention, by prescribing rifampicin as a mixture combined with resveratrol, side effects are reduced, and therefore, long-term administration can be performed on neurodegenerative diseases. In addition, according to the preventive or therapeutic drug of the present invention, even if resveratrol is prescribed as a single agent, the effectiveness of neurodegenerative diseases is shown at very low dosages, and therefore, long-term administration can be performed on neurodegenerative diseases. Furthermore, according to the food of the present invention, by coordinating resveratrol, long-term intake for the purpose of improving brain function can be performed. BRIEF DESCRIPTION OF THE DRAWINGS

[0052] Figure 1 These are the results of the behavioral test performed in Test Example 1, and show the effect of administration of rifampicin on the cognitive function of mice.

[0053] Figure 2These are the results of immunostaining performed in Test Example 1, and show the Aβ oligomer removal effect and synaptophysin restoration effect by rifampicin.

[0054] Figure 3 Indicates based on Figure 2 Quantification results of immunostaining of Aβ oligomers.

[0055] Figure 4 Indicates based on Figure 2 Quantification results of immunostaining for synaptophysin.

[0056] Figure 5 This is the result of immunostaining performed in Test Example 1, and shows the removal effect of phosphorylated Tau by rifampicin.

[0057] Figure 6 Indicates based on Figure 5 Quantification results of immunostaining for phosphorylated Tau.

[0058] Figure 7 The results of the motor function test on 6-month-old (6mo) αSyn-Tg mice used in Test Example 2 are shown.

[0059] Figure 8 The results of the cognitive function test on 9-month-old (9mo) αSyn-Tg mice used in Test Example 2 are shown.

[0060] Fig. 9 These are the results of the behavioral test performed in Test Example 2, and show the effect of administration of rifampicin on the cognitive function of mice.

[0061] Fig.10 This is the result of Western blotting performed in Test Example 2, and shows the effect of rifampicin on α-synuclein.

[0062] Fig.11 Indicates based on Fig.10 Quantification results of α-synuclein by western blotting.

[0063] Fig.12 These are the results of the behavioral test performed in Test Example 3, and show the effect of administration of rifampicin (in combination with resveratrol) on the cognitive function of Alzheimer's disease model mice.

[0064] Fig.13 This is the result of immunostaining performed in Test Example 3, and shows the effect of removing Aβ oligomers by rifampicin (in combination with resveratrol).

[0065] Fig.14 This is the result of AST measurement performed in Test Example 3, and shows the degree of liver dysfunction caused by the administration of rifampicin (in combination with resveratrol).

[0066] Fig.15 These are the results of the behavioral test performed in Test Example 4, and show the effect of administration of rifampicin (in combination with resveratrol) on the cognitive function of synucleinopathy model mice.

[0067] Fig.16 These are the results of the behavioral test performed in Test Example 5, and show the effect of administration of rifampicin (in combination with resveratrol) on the cognitive function of Tauopathy model mice.

[0068] Fig.17 These are the results of the behavioral test performed in Test Example 6, and show the effect of administration of resveratrol on the cognitive function of Alzheimer's disease model mice. DETAILED DESCRIPTION

[0069] [1. A preventive or therapeutic drug for neurodegenerative diseases comprising a combination of rifampicins and resveratrols]

[0070] The first preventive or therapeutic drug of the present invention (hereinafter also referred to as the first pharmaceutical product of the present invention) is characterized in that it contains rifampics and resveratrols and is used for the prevention or treatment of neurodegenerative diseases, wherein the rifampics are selected from the group consisting of rifampicin, its derivatives and salts thereof, and the resveratrols are selected from the group consisting of resveratrol and its derivatives.

[0071] [Rifampicin]

[0072] The first pharmaceutical product of the present invention comprises rifampicins selected from the group consisting of rifampicin, its derivatives and salts thereof. Rifampicin is a well-known ingredient as an antibiotic.

[0073] In the first pharmaceutical of the present invention, rifampicins act as an active ingredient for removing oligomers of the cause protein of neurodegenerative diseases. For example, it has the effect of removing the following substances: oligomers of β-amyloid protein (Aβ) as the cause protein of Alzheimer's disease (AD), oligomers of Tau as the cause protein of Tau protein disease, and oligomers of α-synuclein as the cause protein of synuclein disease. It is believed that rifampicins have naphthohydroquinone or naphthoquinone structure, which contributes to the effect of free radical scavenger as rifampicin. In addition, rifampicin is also excellent in the inhibitory effect of aggregation toxicity of the cause protein of neurodegenerative diseases. For example, the inventor has confirmed that it can completely inhibit the toxicity caused by Aβ42 with higher aggregation ability and strong neurotoxicity.

[0074] Rifampicin is generally a compound represented by the following formula (I).

[0075] [Chemical formula 1]

[0076]

[0077] As a derivative of rifampicin, there is no particular limitation as long as it is a substance having a naphthohydroquinone or naphthoquinone structure and pharmacologically permitted, and examples thereof include 3-formyl rifamycin SV, rifamycin S, rifamycin B, rifamycin SV, and the main active metabolite 25-deacetyl rifampicin. Among the rifampicin derivatives, from the viewpoint of inhibiting the induction of resistant bacteria caused by long-term administration, derivatives having no 3-substituent of the 1,4-dihydroxynaphthalene structure that bears antibiotic activity, such as rifamycin SV, are preferred. These rifampicin derivatives may be used alone or in combination of two or more.

[0078] As the salt of rifampicin, as long as it is a compound that forms a salt with rifampicin or a derivative of rifampicin and is pharmaceutically acceptable, there is no particular limitation. For example, salts of alkali metals (potassium, sodium, etc.), salts of alkaline earth metals (calcium, magnesium, etc.), ammonium salts, salts of pharmaceutically acceptable organic amines (tetramethylammonium, triethylamine, methylamine, dimethylamine, cyclopentylamine, benzylamine, phenethylamine, piperidine, monoethanolamine, diethanolamine, tris (hydroxymethyl) aminomethane, lysine, arginine, N-methyl-D-glucamine, etc.), inorganic acid salts (hydrochloride, hydrobromide, hydroiodide, sulfate, phosphate, nitrate, etc.), organic acid salts (acetate, lactate, tartrate, benzoate, citrate, methanesulfonate, ethanesulfonate, benzenesulfonate, toluenesulfonate, isethionate, glucuronic acid, gluconate, etc.) can be cited. These salts can be used alone or in combination of two or more.

[0079] As the rifampicin, one kind may be selected from rifampicin, a salt of rifampicin, a derivative of rifampicin, and a salt of a derivative of rifampicin and used, or two or more kinds may be used in combination.

[0080] Among the above-mentioned rifampicins, rifampicin and rifamycin SV are preferred.

[0081] In the first pharmaceutical product of the present invention, the content of rifampicin is not particularly limited, and it is appropriately adjusted in a manner that can be administered in the dosage described later. For example, as the content of rifampicin in the first pharmaceutical product of the present invention, it can be mentioned: 0.19w / v% or more, preferably 0.4w / v% or more, more preferably 0.5w / v% or more. In addition, from the viewpoint of effectively administering a given dosage with a small number of administrations, the content of rifampicin in the first pharmaceutical product of the present invention can be preferably 2w / v% or more, 2.5w / v% or more, 5w / v% or more, or 30w / v% or more. Furthermore, as the content of rifampicin in the first pharmaceutical product of the present invention, 95w / v% or less can be mentioned, preferably 85w / v% or less, or 50w / v% or less can be mentioned. In the case where the first pharmaceutical product of the present invention is prepared for nasal administration, from the viewpoint of obtaining a good sprayability of the medicament for nasal administration, it is preferably 85w / v% or less, or 50w / v% or less. Specific ranges of the content of rifampicins in the first pharmaceutical product of the present invention include, for example, 0.19-95 w / v%, 0.19-85 w / v%, 0.19-50 w / v%, 0.4-95 w / v%, 0.4-85 w / v%, 0.4-50 w / v%, 0.5-95 w / v%, 0.5-85 w / v%, 0.5-50 w / v%, 2-95 w / v%, 2-85 w / v%, 2-50 w / v%, 2.5-95 w / v%, 2.5-85 w / v%, 2.5-50 w / v%, 5-95 w / v%, 5-85 w / v%, 5-50 w / v%, 30-95 w / v%, 30-85 w / v%, 30-50 w / v%.

[0082] [Resveratrol]

[0083] The first pharmaceutical product of the present invention comprises resveratrols selected from the group consisting of resveratrol and its derivatives. Resveratrol is 3,5,4'-trihydroxystilbene. Resveratrols are reported to have anti-cancer, dementia prevention (inhibition of Aβ generation), arteriosclerosis / heart disease prevention, anti-metabolism (anti-metabolism), life extension effects, and eye disease prevention. In addition, resveratrols also have a liver-protecting effect. On the other hand, it is not yet known that resveratrol has the effect of removing oligomers of the cause protein of neurodegenerative diseases that have already been produced. In addition, the inventors have confirmed that the effect of inhibiting the aggregation of the cause protein of neurodegenerative diseases caused by resveratrol is weak, for example, the inhibitory effect on the toxicity caused by Aβ42, which has a higher aggregation ability and strong neurotoxicity, is quite weak compared to rifampicin.

[0084] The first pharmaceutical product of the present invention can achieve a significant side effect reduction effect by combining resveratrol and rifampicin. Resveratrol exerts a surprising side effect reduction effect, that is, even at a dose that does not show an effective liver protection effect alone, it still exerts an effective liver protection effect when combined with rifampicin.

[0085] The first pharmaceutical product of the present invention significantly improves the effect of removing oligomers of the causative protein of neurodegenerative diseases by combining resveratrol with rifampicin. Even if resveratrol alone shows an insufficient Aβ production inhibitory effect, when combined with rifampicin, the effect of removing the causative protein of neurodegenerative diseases can be significantly improved.

[0086] Examples of resveratrol in the present invention include cis-isomers of resveratrol, trans-isomers of resveratrol, and mixtures of these isomers, and preferably trans-isomers of resveratrol are used. The trans-isomer of resveratrol is a compound represented by the following formula (II).

[0087] [Chemical formula 2]

[0088]

[0089] Resveratrol may be purified from plant extracts such as bilberry extract, grape extract, bilberry extract, knotweed extract, melinjo extract, etc., or may be obtained by chemical synthesis, genetic engineering, or microbiological methods.

[0090] In addition, as a derivative of resveratrol, there is no particular limitation as long as it is pharmacologically permitted, and examples thereof include: protective groups such as N-phenylacetyl and 4,4'-dimethoxytrityl (DMT); biological macromolecules such as proteins, peptides, sugars, lipids, and nucleic acids; synthetic macromolecules such as polystyrene, polyethylene, polyvinyl, and polyester; substances having functional groups such as ester groups as derivative groups. In addition, as the above-mentioned ester groups, examples thereof include: aliphatic ester groups such as methyl ester groups and ethyl ester groups, and aromatic ester groups.

[0091] As the resveratrols, one kind may be selected from resveratrol and resveratrol derivatives and used, or two or more kinds may be used in combination.

[0092] Among these resveratrols, preferably resveratrol is used, and more preferably the trans isomer of resveratrol (3,5,4′-trihydroxy-trans-stilbene) is used.

[0093] As the content of resveratrol in the first pharmaceutical of the present invention, there is no particular limitation, and it is appropriately adjusted in a manner that can be administered in the dosage described later. For example, as the content of resveratrol in the first pharmaceutical of the present invention, 0.19w / v% or more, preferably 0.4w / v% or more, and more preferably 0.5w / v% or more can be cited. In addition, from the viewpoint of efficiently administering a given dosage with a small number of administrations, the content of resveratrol in the first pharmaceutical of the present invention can be preferably 2w / v% or more, 2.5w / v% or more, 5w / v% or more, or 30w / v% or more. Furthermore, as the content of resveratrol in the first pharmaceutical of the present invention, 95w / v% or less can be cited, preferably 85w / v% or less, or 50w / v% or less. In the case where the first pharmaceutical of the present invention is prepared for nasal administration, from the viewpoint of obtaining the sprayability of the nasal administration agent well, 85w / v% or less, or 50w / v% or less is preferably cited. Specific ranges of the content of resveratrol in the first pharmaceutical product of the present invention include, for example, 0.19-95 w / v%, 0.19-85 w / v%, 0.19-50 w / v%, 0.4-95 w / v%, 0.4-85 w / v%, 0.4-50 w / v%, 0.5-95 w / v%, 0.5-85 w / v%, 0.5-50 w / v%, 2-95 w / v%, 2-85 w / v%, 2-50 w / v%, 2.5-95 w / v%, 2.5-85 w / v%, 2.5-50 w / v%, 5-95 w / v%, 5-85 w / v%, 5-50 w / v%, 30-95 w / v%, 30-85 w / v%, 30-50 w / v%.

[0094] In the first pharmaceutical of the present invention, the ratio of rifampicins to resveratrols is not particularly limited and can be determined according to the content of each component mentioned above. In addition, when the first pharmaceutical of the present invention is prepared for nasal administration, considering the difference between the solubility of rifampicins in water (for example, 2.5 mg / mL at 25°C in the case of rifampicins) and the solubility of resveratrols in water (for example, 0.03 mg / mL at 25°C in the case of resveratrol), and the tendency that the lower the solubility in water, the easier it is to flow to the digestive tract under the influence of the movement of the mucus layer caused by ciliated cells in the nasal cavity, the more resveratrols can be prepared in a manner that is greater than a given effective amount. For example, when the first pharmaceutical of the present invention is prepared for the purpose of allowing rifampicins and resveratrols to be absorbed from the paranasal cavity at a weight ratio of about 1:1, it can also be prepared with a content of more than 1 part by weight of resveratrols per 1 part by weight of rifampicins. As described above, as a case where the difference in solubility of rifampicins and resveratrols in water is taken into consideration, there can be cited a case where the first pharmaceutical of the present invention is prepared as a combination of rifampicins and resveratrols, a case where the first pharmaceutical of the present invention is prepared as a kit comprising a drug containing rifampicins and a drug containing resveratrols and both drugs are prepared using the same base containing at least water.

[0095] From these viewpoints, as the lower limit of the content of resveratrols per 1 weight part of rifampicin, for example, 1 / 500 weight part or more, preferably 1 / 300 weight part or more, more preferably 1 / 200 weight part or more, further preferably 1 / 100 weight part or more, more preferably 0.05 weight part or more, further preferably 0.1 weight part or more, particularly preferably 0.2 weight part or more can be cited. From the viewpoint of obtaining a further preferred side effect reduction effect, and / or obtaining a further preferred neurodegenerative disease cause protein oligomer removal effect, as the content of resveratrols per 1 weight part of rifampicin, preferably 0.5 weight part or more, more preferably 0.8 weight part or more, further preferably 1 weight part or more can be cited. In addition, as the content of resveratrols per 1 weight part of rifampicin, it can be more than 1 weight part, for example, 1.2 weight parts or more, 1.5 weight parts or more, 2 weight parts or more, 3 weight parts or more.

[0096] In addition, the upper limit of the content of resveratrols per 1 part by weight of rifampicins may be, for example, 500 parts by weight or less, preferably 300 parts by weight or less, more preferably 200 parts by weight or less, further preferably 100 parts by weight or less, 75 parts by weight or less, 50 parts by weight or less, 30 parts by weight or less, 20 parts by weight or less, more preferably 10 parts by weight or less, further preferably 5 parts by weight or less, particularly preferably 3 parts by weight or less, 2 parts by weight or less, 1.5 parts by weight or less, or 1.2 parts by weight or less.

[0097] Specific ranges of the content of resveratrols per 1 part by weight of rifampicins include 1 / 500 to 500 parts by weight, 1 / 500 to 300 parts by weight, 1 / 500 to 200 parts by weight, 1 / 500 to 100 parts by weight, 1 / 500 to 75 parts by weight, 1 / 500 to 50 parts by weight, 1 / 500 to 30 parts by weight, 1 / 500 to 20 parts by weight, 1 / 500 to 10 parts by weight, 1 / 500 to 5 parts by weight, 1 / 500 to 3 parts by weight, 1 / 500 to 2 parts by weight, 1 / 500 to 1.5 parts by weight, 1 / 500 to 1.2 parts by weight, 1 / 300 to 500 parts by weight, 1 / 300 to 300 parts by weight, 1 / 300 to 20 parts by weight, 1 / 300 to 100 parts by weight. parts by weight, 1 / 300 to 75 parts by weight, 1 / 300 to 50 parts by weight, 1 / 300 to 30 parts by weight, 1 / 300 to 20 parts by weight, 1 / 300 to 10 parts by weight, 1 / 300 to 5 parts by weight, 1 / 300 to 3 parts by weight, 1 / 300 to 2 parts by weight, 1 / 300 to 1.5 parts by weight, 1 / 300 to 1.2 parts by weight, 1 / 200 to 500 parts by weight, 1 / 200 to 300 parts by weight, 1 / 200 to 200 parts by weight, 1 / 200 to 100 parts by weight, 1 / 200 to 75 parts by weight, 1 / 200 to 50 parts by weight, 1 / 200 to 30 parts by weight, 1 / 200 to 20 parts by weight, 1 / 200 to 10 parts by weight, 1 / 200 to 5 parts by weight, 1 / 20 0 to 3 parts by weight, 1 / 200 to 2 parts by weight, 1 / 200 to 1.5 parts by weight, 1 / 200 to 1.2 parts by weight, 1 / 100 to 500 parts by weight, 1 / 100 to 300 parts by weight, 1 / 100 to 200 parts by weight, 1 / 100 to 100 parts by weight, 1 / 100 to 75 parts by weight, 1 / 100 to 50 parts by weight, 1 / 100 to 30 parts by weight, 1 / 100 to 20 parts by weight, 1 / 100 to 10 parts by weight, 1 / 100 to 5 parts by weight, 1 / 100 to 3 parts by weight, 1 / 100 to 2 parts by weight, 1 / 100 to 1.5 parts by weight, 1 / 100 to 1.2 parts by weight, 0.05 to 500 parts by weight, 0.05 to 300 parts by weight, 0.05 to 200 parts by weight , 0.05-100 parts by weight, 0.05-75 parts by weight, 0.05-50 parts by weight, 0.05-30 parts by weight, 0.05-20 parts by weight, 0.05-10 parts by weight, 0.05-5 parts by weight, 0.05-3 parts by weight, 0.05-2 parts by weight, 0.05-1.5 parts by weight, 0.05-1.2 parts by weight, 0.1-500 parts by weight, 0.1-300 parts by weight, 0.1-200 parts by weight, 0.1-100 parts by weight, 0.1-75 parts by weight, 0.1-50 parts by weight, 0.1-30 parts by weight, 0.1-20 parts by weight, 0.1-10 parts by weight, 0.1-5 parts by weight, 0.1-3 parts by weight, 0.1-2 parts by weight, 0.1-1.5 parts by weight, 0.1-1.2 parts by weight, 0.2-500 parts by weight, 0.2-300 parts by weight, 0.2-200 parts by weight, 0.2-100 parts by weight, 0.2-75 parts by weight, 0.2-50 parts by weight, 0.2-30 parts by weight, 0.2-20 parts by weight, 0.2-10 parts by weight, 0.2-5 parts by weight, 0.2-3 parts by weight, 0.2-2 parts by weight, 0.2 ~1.5 parts by weight, 0.2~1.2 parts by weight, 0.5~500 parts by weight, 0.5~300 parts by weight, 0.5~200 parts by weight, 0.5~100 parts by weight, 0.5~75 parts by weight, 0.5~50 parts by weight, 0.5~30 parts by weight, 0.5~20 parts by weight, 0.5~10 parts by weight, 0.5~5 parts by weight, 0.5~3 parts by weight, 0.5~2 parts by weight, 0.5-1.5 parts by weight, 0.5-1.2 parts by weight, 0.8-500 parts by weight, 0.8-300 parts by weight, 0.8-200 parts by weight, 0.8-100 parts by weight, 0.8-75 parts by weight, 0.8-50 parts by weight, 0.8-30 parts by weight, 0.8-20 parts by weight, 0.8-10 parts by weight, 0.8-5 parts by weight, 0.8-3 parts by weight, 0.8-2 parts by weight parts by weight, 0.8-1.5 parts by weight, 0.8-1.2 parts by weight, 1-500 parts by weight, 1-300 parts by weight, 1-200 parts by weight, 1-100 parts by weight, 1-75 parts by weight, 1-50 parts by weight, 1-30 parts by weight, 1-20 parts by weight, 1-10 parts by weight, 1-5 parts by weight, 1-3 parts by weight, 1-2 parts by weight, 1-1.5 parts by weight, 1-1.2 parts by weight.

[0098] In addition, the specific range of the content of resveratrol per 1 weight part of rifampicin can be 1.2-500 weight parts, 1.2-300 weight parts, 1.2-200 weight parts, 1.2-100 weight parts, 1.2-75 weight parts, 1.2-50 weight parts, 1.2-30 weight parts, 1.2-20 weight parts, 1.2-10 weight parts, 1.2-5 weight parts, 1.5-500 weight parts, 1.5-300 weight parts, 1.5-200 weight parts, 1.5-100 weight parts, 1.5-75 weight parts, 1.5-50 weight parts, 1.5- 30 parts by weight, 1.5-20 parts by weight, 1.5-10 parts by weight, 1.5-5 parts by weight, 2-500 parts by weight, 2-300 parts by weight, 2-200 parts by weight, 2-100 parts by weight, 2-75 parts by weight, 2-50 parts by weight, 2-30 parts by weight, 2-20 parts by weight, 2-10 parts by weight, 2-5 parts by weight, 3-500 parts by weight, 3-300 parts by weight, 3-200 parts by weight, 3-100 parts by weight, 3-75 parts by weight, 3-50 parts by weight, 3-30 parts by weight, 3-20 parts by weight, 3-10 parts by weight, 3-5 parts by weight.

[0099] [Dosage form]

[0100] The first pharmaceutical product of the present invention is a product prepared by a known method by combining the above-mentioned rifampicins and resveratrols. Depending on the administration method of the first pharmaceutical product, a pharmacologically acceptable base and / or additive may be appropriately mixed therewith.

[0101] As pharmacologically acceptable bases and / or additives, for example, excipients, thickeners, lubricants, binders, disintegrants, solvents, solubilizers, suspending agents, emulsifiers, tonicity agents, buffers, pain-relieving agents, stabilizers, etc. In addition, additives such as preservatives (preservatives), pH adjusters, cooling agents, antioxidants, wetting agents, adhesives, and flavor correctives may be included as needed.

[0102] Examples of excipients include lactose, sucrose, D-mannitol, starch, corn starch, crystalline cellulose, light anhydrous silicic acid, etc. Examples of thickeners include polyols such as glycerol and polyethylene glycol, celluloses such as methylcellulose, carboxymethylcellulose, and hydroxypropylmethylcellulose, polyvinyl alcohol, polyvinyl pyrrolidone, carboxyvinyl polymers, sodium carboxymethylcellulose, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, and the like (preferably sodium carboxymethylcellulose) hydrophilic polymers, sodium alginate, chondroitin sulfate, cyclodextrin, d-α-tocopheryl polyethylene glycol 1000 succinate (d-α-tocopheryl polyethylene glycol 1000 succinate), polyethylene glycol, etc. Examples of lubricants include magnesium stearate, calcium stearate, talc, colloidal silicon dioxide, etc. As binders, for example, crystalline cellulose, white sugar, D-mannitol, dextrin, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinyl pyrrolidone, starch, sucrose, gelatin, methyl cellulose, sodium carboxymethyl cellulose, etc. As disintegrants, for example, starch, carboxymethyl cellulose, carboxymethyl cellulose calcium, cross-linked sodium carboxymethyl cellulose, sodium carboxymethyl starch, L-hydroxypropyl cellulose, etc. As solvents, for example, water, ethanol, isopropanol, acetone, propylene glycol, polyethylene glycol, sesame oil, corn oil, etc., preferably at least water. As solubilizers, for example, celluloses such as methyl cellulose, carboxymethyl cellulose, and hydroxypropyl methyl cellulose; polyethylene glycol, propylene glycol, D-mannitol, benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, sodium citrate, polyvinyl pyrrolidone, polyethylene glycol, etc. Examples of suspending agents include stearyl triethanolamine, sodium lauryl sulfate, lauryl aminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride, glyceryl monostearate, polyoxyethylene hydrogenated castor oil, surfactants such as polysorbate, polyols such as glycerol and polyethylene glycol, sugars such as sorbitol, mannitol, sucrose, celluloses such as methylcellulose, carboxymethylcellulose, hydroxypropylmethylcellulose, polyvinyl alcohol, polyvinyl pyrrolidone, carboxyvinyl polymer, sodium carboxymethylcellulose, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, and hydrophilic polymers such as chondroitin sulfate, etc. Examples of tonicity agents include glucose, D-sorbitol, sodium chloride, glycerol, D-mannitol, potassium chloride, concentrated glycerol, propylene glycol, sucrose, etc. Examples of the buffer include phosphates (sodium hydrogen phosphate, sodium dihydrogen phosphate, etc.), boric acid, borax, acetates (sodium acetate, etc.), carbonates (sodium carbonate, calcium carbonate, potassium carbonate, etc.), citric acid, sodium L-glutamate, etc. Examples of the placebo include benzyl alcohol, chlorobutanol, propylene glycol, ethyl aminobenzoate, lidocaine, etc.Examples of the stabilizer include sodium sulfite, sodium bisulfite, sodium metabisulfite, sodium thiosulfate, Rongalite, thioglycerol, thioglycolic acid, thiolactic acid, cysteine, glutathione, thioacetic acid, methionine, thiosorbitol, thioglucose, sulfur compounds such as thiourea, boric acid, borax, phosphoric acid, metaphosphoric acid, sodium carbonate, sodium bicarbonate and their salts, formic acid, oxalic acid, tartaric acid, citric acid, Organic acids such as ethylenediaminetetraacetic acid and their salts (such as sodium ethylenediaminetetraacetic acid), amides such as acetamide, diethylacetamide, niacinamide, urea, and barbiturates; urea derivatives, ethylene glycol, propylene glycol, glycerol, polyethylene glycol, glucose, ascorbic acid and other polyols, sugars, phenols such as thymol, quinone, coumarone, and isocoumarone; butylated hydroxytoluene, glycine, glutamic acid, lysine, phenylalanine, casein, edema globulin and other amino acids, proteins, etc. Examples of the emulsifier include glycerides (monoolein), saponins (sophora japonica saponin, quillaja bark extract, soybean saponin, etc.), sucrose fatty acid esters, lecithin (vegetable lecithin, egg yolk lecithin, soybean lecithin, etc.), polyols (oleyl alcohol, stearyl alcohol, cetyl alcohol, etc.), fatty esters (octyldodecyl myristate, etc.), medium-chain fatty acid triglycerides (MCT), various surfactants (alkylbenzene sulfonate emulsifiers, benzalkonium chloride, sorbitan sesquioleate, dodecylbenzenesulfonic acid, etc.), triethanolamine, etc. As preservatives, for example, parabens such as propylparaben and butylparaben, parabens such as methylparaben, ethylparaben, propylparaben, and butylparaben, inverse soaps such as benzalkonium chloride, benzethonium chloride, chlorhexidine gluconate, and cetylpyridinium chloride, alcohol derivatives such as chlorobutanol, benzyl alcohol, and phenethyl alcohol, organic acids such as sodium dehydroacetate, sorbic acid, and sodium sorbate, and salts thereof, phenols such as p-chloromethoxyphenol and p-chloro-meta-cresol, etc. As pH adjusters, for example, sodium hydroxide, potassium hydroxide, trisodium phosphate, disodium hydrogen phosphate, hydrochloric acid, nitric acid, citric acid, boric acid, and acetic acid, etc. As cooling agents, for example, 1-menthol, camphor, and mint water, etc., can be mentioned. Examples of antioxidants include sulfites, ascorbic acid, citric acid, sodium edetate, etc. Examples of wetting agents include propylene glycol, polysorbate, polyethylene glycol, glycerol, etc. Examples of binders include hydroxypropyl cellulose, hydroxypropyl methylcellulose 2208, carboxyvinyl polymer, propylene glycol, polysorbate 80, etc. Examples of deodorants include trehalose, malic acid, maltose, potassium gluconate, fennel essential oil, vanilla essential oil, cardamom essential oil, herbal ingredients, etc.

[0103] The first pharmaceutical of the present invention can be any one of a liquid agent and a solid agent, preferably a liquid agent. In the case of a liquid agent, it can be manufactured by mixing, dissolving, suspending or emulsifying rifampicins and resveratrols, and solvents, solubilizers, suspending agents, tonicity agents, buffers, pain-relieving agents, etc. as needed. In the case where the first pharmaceutical of the present invention is prepared as a nasal administration agent, it is also preferred to further add a thickening agent to increase viscosity and impart retention. In the case of a solid agent, it can be manufactured by the following method: rifampicins and resveratrols, and excipients, binders, disintegrants or other appropriate additives as needed are uniformly mixed, and granules are obtained by a suitable granulation method, and further made into powder or microgranules by suitable drying.

[0104] When the first pharmaceutical product of the present invention is prepared as a nasal drug, it can be filled in a container for nasal administration and used. As the container for nasal administration, a commercially available container can be used as appropriate.

[0105] As a more specific example of the first pharmaceutical product of the present invention, a combination of rifampicins and resveratrols can be cited. The combination is a pharmaceutical composition containing rifampicins and resveratrols in a mixed state. According to the combination, rifampicins and resveratrols can be administered simultaneously in any administration method.

[0106] As other examples of more specific forms of the first pharmaceutical of the present invention, a test kit containing a medicament comprising rifampicins and a medicament comprising resveratrols can be enumerated. Each medicament can be prepared using the same base and / or additive, or can be prepared using a base and / or additive selected according to rifampicins and resveratrols, respectively. According to the test kit, rifampicins and resveratrols can be administered respectively in any administration mode. In addition, in the case of a nasal administration device having a cartridge filled with a medicament containing rifampicins and another cartridge filled with a medicament containing resveratrols in a nasal administration device, although it is a test kit, two components can also be administered simultaneously.

[0107] [Dosage and Usage]

[0108] The first pharmaceutical of the present invention can significantly reduce the side effects by combining resveratrol with rifampicin, and can be administered for a long time. In addition, the first pharmaceutical of the present invention can significantly improve the removal effect of protein oligomers caused by neurodegenerative diseases by combining resveratrol with rifampicin, so it can be administered in a dosage less than the effective amount of an antibiotic. Therefore, the first pharmaceutical of the present invention can be continuously administered for a longer time than when administered as an antibiotic with a dosage less than when administered as an antibiotic. The pharmaceutical composition of the present invention can be prepared into any one of the administration methods for oral administration, subcutaneous administration and nasal administration. Among them, the first pharmaceutical of the present invention is non-invasive, and is more preferably prepared for nasal administration from the viewpoint of obtaining a further preferred side effect reduction effect, and then from the viewpoint of administration with a smaller dosage and / or longer-term administration.

[0109] Since the first pharmaceutical product of the present invention has significantly reduced side effects, the dosage of the first pharmaceutical product of the present invention for humans, as a dosage of rifampicin, can be a dosage lower than the dosage when administered as an antibiotic (e.g., 7.5 to 10 mg / kg·day). For example, as a dosage of rifampicin, less than 1 / 2, preferably less than 1 / 3, and more preferably less than 1 / 3.75 of the dosage when administered as an antibiotic (e.g., 7.5 to 10 mg / kg·day) can be cited. In the case where the first pharmaceutical product of the present invention is prepared for nasal administration, as a dosage of rifampicin, less than 1 / 5 of the dosage when administered orally as an antibiotic (e.g., 7.5 to 10 mg / kg·day) can be cited.

[0110] More specifically, regarding the dosage of the first pharmaceutical product of the present invention for humans, the lower limit of the dosage of rifampicin, from the viewpoint of showing drug efficacy, can be 0.15 mg / kg·day or more, preferably 0.3 mg / kg·day or more, more preferably 0.75 mg / kg·day or more, and further preferably 1 mg / kg·day or more. In addition, as the upper limit of the dosage of rifampicin for humans, from the viewpoint of suppressing side effects, can be 3.75 mg / kg·day or less, preferably 2.5 mg / kg·day or less, and more preferably 2 mg / kg·day or less.

[0111] In addition, when the first pharmaceutical product of the present invention is prepared for nasal administration, the dosage of rifampicin can be even less. In addition, the first pharmaceutical product of the present invention can significantly improve the removal effect of protein oligomers caused by neurodegenerative diseases by combining resveratrols with rifampicins, so even if rifampicins are used in an amount that does not show an effective removal effect of protein caused by neurodegenerative diseases alone, in combination with rifampicins, the removal effect of protein caused by neurodegenerative diseases can also be effectively exerted. In view of the effect of rifampicins caused by combining with resveratrols, as the lower limit of the dosage of rifampicins to humans, from the perspective of showing drug efficacy, for example, 0.001 mg / kg·day or more, preferably 0.002 mg / kg·day or more, more preferably 0.003 mg / kg·day or more, further preferably 0.005 mg / kg·day or more, more preferably 0.01 mg / kg·day or more. From the viewpoint of showing a more preferred drug effect, the lower limit of the dosage of rifampicin for humans can be, for example, 0.025 mg / kg·day or more, preferably 0.05 mg / kg·day or more, and more preferably 0.1 mg / kg·day or more. Furthermore, from the viewpoint of suppressing further side effects, the upper limit of the dosage of rifampicin for humans can be 1.5 mg / kg·day or less, preferably 1 mg / kg·day or less, more preferably 0.5 mg / kg·day or less, further preferably 0.1 mg / kg·day or less, and more preferably 0.07 mg / kg·day or less.

[0112] Specific ranges of the dosage of rifampicin as the first pharmaceutical agent of the present invention include: 0.001 to 3.75 mg / kg·day, 0.001 to 2.5 mg / kg·day, 0.001 to 2 mg / kg·day, 0.001 to 1.5 mg / kg·day, 0.001 to 1 mg / kg·day, 0.001 to 0.5 mg / kg·day, 0.001 to 0.1 mg / kg·day, 0.001 to 0.07 mg / kg·day, 0.002 to 3.75 mg / kg·day, 0.002 to 2.5 mg / kg·day, 0.002 to 2 mg / kg·day, 0.002 to 1.5 mg / kg·day, 0.002 to 1 mg / kg·day, 0.0 0.2~0.5mg / kg·day, 0.002~0.1mg / kg·day, 0.002~0.07mg / kg·day, 0.003~3.75mg / kg·day, 0.003~2.5mg / kg·day, 0.003~2mg / kg·day, 0.003~1.5mg / kg·day, 0.003~1mg / kg·day, 0.003~0.5mg / kg·day, 0.003~0.1mg / kg·day, 0.003~0.07mg / kg·day, 0.005~3.75mg / kg·day, 0.005~2.5mg / kg·day, 0.005~2mg / kg·day, 0.005~1.5mg / kg·day, 0.005-1mg / kg·day, 0.005-0.5mg / kg·day, 0.005-0.1mg / kg·day, 0.005-0.07mg / kg·day, 0.01-3.75mg / kg·day, 0.01-2.5mg / kg·day, 0.01-2mg / kg·day, 0.01-1.5mg / kg·day, 0.01-1mg / kg·day, 0.01-0.5mg / kg·day, 0.01-0.1mg / kg·day, 0.01-0.07mg / kg·day, 0.025-3.75mg / kg·day, 0.025-2.5mg / kg·day, 0.025-2mg / kg·day, 0.025- 1.5mg / kg·day, 0.025~1mg / kg·day, 0.025~0.5mg / kg·day, 0.025~0.1mg / kg·day, 0.025~0.07mg / kg·day, 0.05~3.75mg / kg·day, 0.05~2.5mg / kg·day, 0.05~2mg / kg·day, 0.05~1.5mg / kg·day, 0.05~1mg / kg·day, 0.05~0.5mg / kg·day, 0.05~0.1mg / kg·day, 0.05~0.07mg / kg·day, 0.1~3.75mg / kg·day, 0.1~2.5mg / kg·day, 0.1~2mg / kg·day, 0.1-1.5 mg / kg·day, 0.1-1 mg / kg·day, 0.1-0.5 mg / kg·day, 0.15-3.75 mg / kg·day, 0.15-2.5 mg / kg·day, 0.15-2 mg / kg·day, 0.15-1.5 mg / kg·day, 0.15-1 mg / kg·day, 0.15-0.5 mg / kg·day, 0.3-3.75 mg / kg·day, 0.3 ~2.5mg / kg·day, 0.3~2mg / kg·day, 0.3~1.5mg / kg·day, 0.75~3.75mg / kg·day, 0.75~2.5mg / kg·day, 0.75~2mg / kg·day, 0.75~1.5mg / kg·day, 1~3.75mg / kg·day, 1~2.5mg / kg·day, 1~2mg / kg·day, 1~1.5mg / kg·day. .

[0113] Regarding the dosage of the first pharmaceutical product of the present invention to a human being, as the dosage of resveratrol, from the viewpoint of reducing side effects and improving the effect of removing protein oligomers that cause neurodegenerative diseases, for example, 0.025 mg / kg·day or more, preferably 0.05 mg / kg·day or more, more preferably 0.1 mg / kg·day or more, further preferably 0.15 mg / kg·day or more, more preferably 0.3 mg / kg·day or more, further preferably 0.75 mg / kg·day or more, and particularly preferably 1 mg / kg·day or more can be cited. The upper limit of the dosage of resveratrol to a human being is not particularly limited, and for example, 3.75 mg / kg·day or less can be cited.

[0114] In addition, even if the resveratrol combined with rifampicin is a dosage that does not show an effective liver protection effect alone, it also exerts an effective liver protection effect when combined with rifampicin. Furthermore, it is not known that the resveratrol combined with rifampicin itself has the effect of removing oligomers of the causative protein of neurodegenerative diseases that have already been produced, and the inventors have found that it has the effect of removing oligomers of the causative protein of neurodegenerative diseases. In the present invention, even if the resveratrol is a dosage that only shows a slow Aβ generation inhibitory effect alone, when combined with rifampicin, the effect of removing the causative protein of neurodegenerative diseases is significantly improved. In view of the effects caused by such resveratrol, as the lower limit of the dosage of resveratrols to humans, from the perspective of showing drug efficacy, for example, 0.001 mg / kg·day or more, preferably 0.002 mg / kg·day or more, more preferably 0.003 mg / kg·day or more, further preferably 0.005 mg / kg·day or more, and most preferably 0.01 mg / kg·day or more can also be cited, and as the upper limit of the dosage of resveratrols to humans, preferably 2.5 mg / kg·day or less, more preferably 2 mg / kg·day or less, and further preferably 1.5 mg / kg·day or less can also be cited. Furthermore, as the upper limit of the dosage of resveratrols to humans, it is preferably 1 mg / kg·day or less, more preferably 0.5 mg / kg·day or less, further preferably 0.1 mg / kg·day or less, and more preferably 0.07 mg / kg·day or less.

[0115] Specific ranges of the dosage of resveratrol in the first pharmaceutical product of the present invention include: 0.001 to 3.75 mg / kg·day, 0.001 to 2.5 mg / kg·day, 0.001 to 2 mg / kg·day, 0.001 to 1.5 mg / kg·day, 0.001 to 1 mg / kg·day, 0.001 to 0.5 mg / kg·day, 0.001 to 0.1 mg / kg·day, 0.001 to 0.07 mg / kg·day, 0.002 to 3.75 mg / kg·day, 0.002 to 2.5 mg / kg·day, 0.002 to 2 mg / kg·day, 0.002 to 1.5 mg / kg·day, 0.002 to 1 mg / kg·day, 0.002 to 0.5 mg / kg·day, 0.001 to 0.1 mg / kg·day, 0.001 to 0.07 mg / kg·day, .002~0.5mg / kg·day, 0.002~0.1mg / kg·day, 0.002~0.07mg / kg·day, 0.003~3.75mg / kg·day, 0.003~2.5mg / kg·day, 0.003~2mg / kg·day, 0.003~1.5mg / kg·day, 0.003~1mg / kg·day, 0.003~0.5mg / kg·day, 0.003~0.1mg / kg·day, 0.003~0.07mg / kg·day, 0.005~3.75mg / kg·day, 0.005~2.5mg / kg·day, 0.005~2mg / kg·day, 0.005~1.5mg / kg· day, 0.005-1mg / kg·day, 0.005-0.5mg / kg·day, 0.005-0.1mg / kg·day, 0.005-0.07mg / kg·day, 0.01-3.75mg / kg·day, 0.01-2.5mg / kg·day, 0.01-2mg / kg·day, 0.01-1.5mg / kg·day, 0.01-1mg / kg·day, 0.01-0.5mg / kg·day, 0.01-0.1mg / kg·day, 0.01-0.07mg / kg·day, 0.025-3.75mg / kg·day, 0.025-2.5mg / kg·day, 0.025-2mg / kg·day, 0.025 ~1.5mg / kg·day, 0.025~1mg / kg·day, 0.025~0.5mg / kg·day, 0.025~0.1mg / kg·day, 0.025~0.07mg / kg·day, 0.05~3.75mg / kg·day, 0.05~2.5mg / kg·day, 0.05~2mg / kg·day, 0.05~1.5mg / kg·day, 0.05~1mg / kg·day, 0.05~0.5mg / kg·day, 0.05~0.1mg / kg·day, 0.05~0.07mg / kg·day, 0.1~3.75mg / kg·day, 0.1~2.5mg / kg·day, 0.1~2mg / kg·day, 0.1-1.5 mg / kg·day, 0.1-1 mg / kg·day, 0.1-0.5 mg / kg·day, 0.15-3.75 mg / kg·day, 0.15-2.5 mg / kg·day, 0.15-2 mg / kg·day, 0.15-1.5 mg / kg·day, 0.15-1 mg / kg·day, 0.15-0.5 mg / kg·day, 0.3-3.75 mg / kg·day, 0.3 ~2.5mg / kg·day, 0.3~2mg / kg·day, 0.3~1.5mg / kg·day, 0.75~3.75mg / kg·day, 0.75~2.5mg / kg·day, 0.75~2mg / kg·day, 0.75~1.5mg / kg·day, 1~3.75mg / kg·day, 1~2.5mg / kg·day, 1~2mg / kg·day, 1~1.5mg / kg·day. .

[0116] The first pharmaceutical of the present invention is suitable for continuous administration because side effects are suppressed. Furthermore, since the first pharmaceutical of the present invention can be administered in a small amount, it is more suitable for continuous administration. As the administration period of the first pharmaceutical of the present invention to a person, for example, more than 1 month, preferably more than 3 months, can be cited. Since the first pharmaceutical of the present invention can be administered for a longer period of time, as a further preferred example of the administration period to a person, for example, more than 6 months, preferably more than 1 year, more preferably more than 1.5 years, further preferably more than 2 years, more preferably more than 2.5 years, can be cited, and in addition, the administration period can be more than 3 years. As the upper limit of the administration period to a person, there is no particular limitation, and for example, less than 10 years, less than 8 years, less than 6 years, or less than 4 years can be cited. In addition, the upper limit of the administration period can be less than 3 years. Specific administration periods include: 1 month to 10 years, 1 month to 8 years, 1 month to 6 years, 1 month to 4 years, 1 month to 3 years, 3 months to 10 years, 3 months to 8 years, 3 months to 6 years, 3 months to 4 years, 3 months to 3 years, 6 months to 10 years, 6 months to 8 years, 6 months to 6 years, 6 months to 4 years, 6 months to 3 years, 1 to 10 years, 1 to 8 years, 1 to 6 years, 1 to 4 years, 1 to 3 years, 1.5 to 10 years, 1.5 to 8 years, 1.5 to 6 years, 1.5 to 4 years, 1.5 to 3 years, 2 to 10 years, 2 to 8 years, 2 to 6 years, 2 to 4 years, 2 to 3 years, 2.5 to 10 years, 2.5 to 8 years, 2.5 to 6 years, 2.5 to 4 years, 2.5 to 3 years, 3 to 10 years, 3 to 8 years, 3 to 6 years, 3 to 4 years. In addition, the dosing interval may be daily, every other day, or 1 to 2 times a week, preferably every other day or every day, and more preferably every day.

[0117] [Target group]

[0118] The first pharmaceutical product of the present invention can be used for the prevention and treatment of neurodegenerative diseases.

[0119] Since the first pharmaceutical of the present invention is suitable for long-term administration, it can be preferably used for the prevention of neurodegenerative diseases. As neurodegenerative diseases, Alzheimer's disease (AD), Tau disease and synuclein disease, etc. can be mentioned. As Tau disease, frontotemporal lobar degeneration (FTLD), AD such as Pick's disease, cortical basal degeneration (CBD), progressive supranuclear palsy (PSP), etc. can be mentioned. As synuclein disease, Lewy body dementia (DLB), Parkinson's disease (PD) and multiple system atrophy (MSA) can be mentioned (preferably Lewy body dementia and Parkinson's disease). When the first pharmaceutical of the present invention is used for the prevention of neurodegenerative diseases, as the subject of administration, as long as it is a non-infected patient with a high risk of morbidity, it is not particularly limited. Examples of undiagnosed patients with a high risk of developing the disease include, in the case of AD, healthy persons who are senile plaque-positive under amyloid imaging, families with familial Alzheimer's disease, etc.; in the case of Tauopathy, healthy persons who are Tau inclusion-positive under Tau imaging, families with familial Tauopathy (FTDP-17, etc.) etc.; in the case of synucleinopathy, healthy persons who are Lewy body-positive under synuclein imaging, healthy persons with abnormal signals under dopamine transporter imaging, families with familial synucleinopathy (familial Parkinson's disease, etc.) etc.

[0120] In addition, since the first pharmaceutical product of the present invention is very excellent in the effect of removing oligomers of the cause protein of neurodegenerative diseases, it can also be used for the treatment of neurodegenerative diseases of the onset. In the case of the treatment of synuclein diseases, as the subject of administration, as long as it is necessary to diagnose synuclein diseases, prevent or improve the patient of the condition (such as cognitive function) of synuclein diseases, there is no particular limitation. It can be preferably applied to patients with Lewy body dementia.

[0121] [Pharmacological action]

[0122] Rifampicin reaches the brain through administration and brings about the following effects: inhibiting the formation or aggregation of oligomers of the causative protein of neurodegenerative diseases, or removing the formed or aggregated oligomers of the causative protein of neurodegenerative diseases. Thus, the onset of neurodegenerative diseases is delayed, or the symptoms of neurodegenerative diseases that have already occurred are improved (e.g., recovery of memory impairment caused by synaptic reactivation).

[0123] In addition, the dendrites of the olfactory epithelial neurons reach the nasal mucosa at the top of the nasal cavity, and the odor information obtained in the olfactory receptors on the cell surface is sent to the olfactory bulb of the brain along the axons of the olfactory epithelial neurons. There is no blood-brain barrier (BBB) ​​between the nasal mucosa and the olfactory epithelial neurons. There is cerebrospinal fluid around the bundles of nerves in which the axons of the olfactory epithelial neurons are bundled, but there is no blood-cerebrospinal fluid barrier (BCSFB) that prevents the exchange of substances between the blood and the cerebrospinal fluid. Therefore, in the case of nasal administration of the first pharmaceutical product of the present invention, the active ingredient rifampicin that reaches the nasal mucosa can enter the olfactory epithelial neurons or cerebrospinal fluid without being hindered by the BBB and BCSFB, and transfer to the brain.

[0124] Thus, when the first pharmaceutical product of the present invention is administered nasally, the direct transfer of rifampicin to the brain is improved, so that the first passage to the liver can be suppressed. Therefore, in this case, the first pharmaceutical product of the present invention is not only non-invasive in terms of the administration form, but also further improves the high efficacy due to the improved direct transfer to the brain, and further achieves a more significant side effect reduction effect due to the inhibition of the first passage to the liver.

[0125] [2. Preventive or therapeutic drugs for neurodegenerative diseases containing resveratrol]

[0126] The second preventive or therapeutic drug of the present invention (hereinafter, also recorded as the second pharmaceutical product of the present invention) is characterized in that it is a pharmaceutical product for nasal administration for the prevention or treatment of neurodegenerative diseases, comprising resveratrols selected from the group consisting of resveratrol and its derivatives, in a given dosage. In addition, the second pharmaceutical product of the present invention contains resveratrols in a single dose. The second pharmaceutical product of the present invention contains resveratrols in a single dose, which means that resveratrols are not used in combination with rifampicins in order to distinguish them from the first pharmaceutical product of the present invention, and other active ingredients are allowed to be included within this limit.

[0127] [Resveratrol]

[0128] The second pharmaceutical product of the present invention comprises resveratrol selected from the group consisting of resveratrol and its derivatives. Although the resveratrol in the second pharmaceutical product of the present invention is a single dose, it can gradually remove oligomers of proteins that cause neurodegenerative diseases and achieve the effect of improving cognitive function by continuous nasal administration at a low dose.

[0129] The details of resveratrols are as described in the above-mentioned "1. A preventive or therapeutic drug for a neurodegenerative disease in which rifampicins and resveratrols are combined". In addition, the content of resveratrols in the second pharmaceutical product of the present invention is the same as the content of resveratrols in the first pharmaceutical product described in the above-mentioned "1. A preventive or therapeutic drug for a neurodegenerative disease in which rifampicins and resveratrols are combined".

[0130] [Dosage form]

[0131] The dosage form of the second pharmaceutical product of the present invention is the same as the dosage form of the first pharmaceutical product described in the above-mentioned "1. Preventive or therapeutic drug for neurodegenerative diseases comprising a combination of rifampicins and resveratrols".

[0132] [Usage and dosage]

[0133] The second pharmaceutical product of the present invention is prepared for nasal administration in order to obtain efficacy against neurodegenerative diseases at a given low dosage. Regarding the dosage of the second pharmaceutical product of the present invention to humans, as a dosage of resveratrol, it is 0.28 mg / kg·day or less. The second pharmaceutical product of the present invention slowly shows its efficacy even at a low dosage, so the dosage of resveratrol can be 0.24 mg / kg·day or less, 0.2 mg / kg·day or less, 0.15 mg / kg·day or less, 0.1 mg / kg·day or less, 0.08 mg / kg·day or less, or 0.06 mg / kg·day or less.

[0134] From the viewpoint of showing the drug effect, the lower limit of the dosage of resveratrol in the second pharmaceutical product of the present invention is, for example, 0.01 mg / kg·day or more, preferably 0.025 mg / kg·day or more, more preferably 0.05 mg / kg·day or more, further preferably 0.1 mg / kg·day or more, more preferably 0.2 mg / kg·day or more, and particularly preferably 0.25 mg / kg·day or more.

[0135] Specific ranges of the dosage of resveratrol in the second pharmaceutical product of the present invention include: 0.01 to 0.28 mg / kg·day, 0.01 to 0.24 mg / kg·day, 0.01 to 0.2 mg / kg·day, 0.01 to 0.15 mg / kg·day, 0.01 to 0.1 mg / kg·day, 0.01 to 0.08 mg / kg·day, 0.01 to 0.06 mg / kg·day, 0.025 to 0.28 mg / kg·day, 0.025 to 0.24 mg / kg·day, 0.025 to 0.2 mg / kg·day, 0.025 to 0.15 mg / kg·day, 0.025 to 0.1 mg / kg·day, 0.025 to 0.08 mg / kg·day kg·day, 0.025~0.06mg / kg·day, 0.05~0.28mg / kg·day, 0.05~0.24mg / kg·day, 0.05~0.2mg / kg·day, 0.05~0.15mg / kg·day, 0.05~0.1mg / kg·day, 0.05~0.08mg / kg·day, 0.05~0.06mg / kg·day, 0.1~0.28mg / kg·day, 0.1~0.24mg / kg·day, 0.1~0.2mg / kg·day, 0.1~0.15mg / kg·day, 0.2~0.28mg / kg·day, 0.2~0.24mg / kg·day, 0.25~0.28mg / kg·day.

[0136] The second pharmaceutical product of the present invention can be administered resveratrol 1 to 4 times a day in the above dosage. As the administration period for humans, for example, more than 1 month, preferably more than 3 months, more preferably more than 6 months, further preferably more than 1 year, and more preferably more than 1.5 years can be cited. Since the first pharmaceutical product of the present invention can be administered for a relatively long period of time, as a further preferred example of the administration period for humans, for example, more than 2.5 years, more preferably more than 2.8 years, and particularly preferably more than 3 years can be cited. As the upper limit of the administration period for humans, there is no particular limitation, and for example, less than 10 years, less than 8 years, less than 6 years, or less than 4 years can be cited. Specific administration periods include 1 month to 10 years, 1 month to 8 years, 1 month to 6 years, 1 month to 4 years, 3 months to 10 years, 3 months to 8 years, 3 months to 6 years, 3 months to 4 years, 6 months to 10 years, 6 months to 8 years, 6 months to 6 years, 6 months to 4 years, 1 to 10 years, 1 to 8 years, 1 to 6 years, 1 to 4 years, 1.5 to 10 years, 1.5 to 8 years, 1.5 to 6 years, 1.5 to 4 years, 2 to 10 years, 2 to 8 years, 2 to 6 years, 2 to 4 years, 2.5 to 10 years, 2.5 to 8 years, 2.5 to 6 years, 2.5 to 4 years, 3 to 10 years, 3 to 8 years, 3 to 6 years, and 3 to 4 years. In addition, administration intervals include daily, every other day, or 1 to 2 times a week. In addition, examples of the administration interval include daily, every other day, or once or twice a week, preferably every other day or every day, and more preferably every day.

[0137] [Target group]

[0138] The second pharmaceutical product of the present invention can be used for the prevention and treatment of neurodegenerative diseases.

[0139] The subjects of administration of the second pharmaceutical product of the present invention are the same as those described in the above-mentioned "1. Preventive or therapeutic agent for neurodegenerative diseases comprising a combination of rifampicins and resveratrols".

[0140] Among them, the second pharmaceutical product of the present invention is preferably used for the prevention of Alzheimer's disease (AD), and specific subjects of administration at this time include healthy people with positive senile plaques under amyloid imaging, families with familial Alzheimer's disease, etc. In addition, the second pharmaceutical product of the present invention can be used for the purpose of improving symptoms caused by brain function failure, specifically cognitive function (such as amnesia), and specific subjects of administration at this time include people with brain function failure, specifically cognitive function failure, and people who want to suppress or improve cognitive function decline with age.

[0141] [3. Foods containing resveratrol to improve brain function]

[0142] The food for improving brain function of the present invention is characterized in that it contains resveratrols selected from the group consisting of resveratrol and its derivatives, and is used for improving brain function in a given amount. In addition, the food for improving brain function of the present invention contains resveratrols in a single dose. The inclusion of resveratrols in a single dose in the food for improving brain function of the present invention is the same as the inclusion of resveratrols in a single dose in the second pharmaceutical product of the present invention.

[0143] [Resveratrol]

[0144] The brain function improving food of the present invention comprises resveratrol selected from the group consisting of resveratrol and its derivatives. The resveratrol in the brain function improving food of the present invention is a single dose, but can exert the effect of improving cognitive function by continuous intake of low doses.

[0145] The details of resveratrols are as described in the above-mentioned "1. A preventive or therapeutic drug for a neurodegenerative disease formed by combining rifampicins and resveratrols". In addition, the content of resveratrols in the food for improving brain function of the present invention is the same as the content of resveratrols in the first pharmaceutical product described in the above-mentioned "1. A preventive or therapeutic drug for a neurodegenerative disease formed by combining rifampicins and resveratrols".

[0146] [Dosage form]

[0147] The dosage form of the food for improving brain function of the present invention may be liquid or solid. Examples of liquids include liquids, beverages, emulsions, suspensions, alcohols, syrups, elixirs, soft extracts, etc., and examples of solids include tablets, pills, powders, fine granules, granules, tablets, capsules (including hard capsules and soft capsules), lozenges, chewable tablets, dry extracts, etc.

[0148] The brain function improving food of the present invention can be used as general food (including beverages), health functional food (including specific health functional food, nutritional functional food, supplements, etc.), patient food, medicine, quasi-drug, and can also be used as an additive to other foods, medicines, quasi-drugs, etc.

[0149] The brain function improving food of the present invention may contain one or more excipients, disintegrants, diluents, lubricants, flavoring agents, colorants, sweeteners, flavoring agents, suspending agents, wetting agents, emulsifiers, dispersants, adjuvants, preservatives, buffers, binders, stabilizers, extenders, thickeners, pH adjusters, surfactants, coating agents, nutrients, etc., which are permitted in food science or pharmacology, depending on the dosage form.

[0150] [Usage and dosage]

[0151] The intake amount of the food for improving brain function of the present invention by humans is 3.75 mg / kg·day or less as the intake amount of resveratrol. Since the food for improving brain function of the present invention slowly shows the efficacy even at a low dosage, the intake amount of resveratrol can be 2.5 mg / kg·day or less, 2 mg / kg·day or less, or 1.5 mg / kg·day or less.

[0152] From the viewpoint of showing the brain function improving effect, the lower limit of the intake of resveratrol in the brain function improving food of the present invention is 0.1 mg / kg·day or more, preferably 0.15 mg / kg·day or more, more preferably 0.3 mg / kg·day or more, further preferably 0.75 mg / kg·day or more, and more preferably 1 mg / kg·day or more.

[0153] Specific ranges of the amount of resveratrol in the brain function improving food of the present invention include: 0.1 to 3.75 mg / kg·day, 0.1 to 2.5 mg / kg·day, 0.1 to 2 mg / kg·day, 0.1 to 1.5 mg / kg·day, 0.15 to 3.75 mg / kg·day, 0.15 to 2.5 mg / kg·day, 0.15 to 2 mg / kg·day, 0.15 to 1.5 mg / kg·day, 0.3 to 3.75 mg / kg·day, 0.15 to 2.5 mg / kg·day, 0.15 to 2 mg / kg·day, 0.15 to 1.5 mg / kg·day, 0.3 to 3.7 5mg / kg·day, 0.3~2.5mg / kg·day, 0.3~2mg / kg·day, 0.3~1.5mg / kg·day, 0.75~3.75mg / kg·day, 0.75~2.5mg / kg·day, 0.75~2mg / kg·day, 0.75~1.5mg / kg·day, 1~3.75mg / kg·day, 1~2.5mg / kg·day, 1~2mg / kg·day, 1~1.5mg / kg·day.

[0154] The food for improving brain function of the present invention can take resveratrol about 1 to 4 times a day in the above-mentioned dosage. As the period of human intake, for example, more than 1 month, preferably more than 3 months, more preferably more than 6 months, further preferably more than 1 year, and more preferably more than 1.5 years can be cited. Since the food for improving brain function of the present invention can be ingested for a relatively long period of time, as a further preferred example of the period of human intake, for example, preferably more than 2.5 years, further preferably more than 2.8 years, and more preferably more than 3 years can be cited. As the upper limit of the period of human intake, there is no particular limitation, and for example, less than 10 years, less than 8 years, less than 6 years, or less than 4 years can be cited. Specific intake periods include 1 month to 10 years, 1 month to 8 years, 1 month to 6 years, 1 month to 4 years, 3 months to 10 years, 3 months to 8 years, 3 months to 6 years, 3 months to 4 years, 6 months to 10 years, 6 months to 8 years, 6 months to 6 years, 6 months to 4 years, 1 to 10 years, 1 to 8 years, 1 to 6 years, 1 to 4 years, 1.5 to 10 years, 1.5 to 8 years, 1.5 to 6 years, 1.5 to 4 years, 2 to 10 years, 2 to 8 years, 2 to 6 years, 2 to 4 years, 2.5 to 10 years, 2.5 to 8 years, 2.5 to 6 years, 2.5 to 4 years, 3 to 10 years, 3 to 8 years, 3 to 6 years, and 3 to 4 years. In addition, intake intervals include daily, every other day, or 1 to 2 times a week, preferably every other day or every day, and more preferably every day.

[0155] [Object of capture]

[0156] The brain function improving food of the present invention can be used for the purpose of improving symptoms caused by brain function failure, specifically improving cognitive function (such as amnesia), and as specific subjects of administration at this time, people with brain function failure, specifically cognitive function failure, and people who hope to suppress or improve the decrease of cognitive function with age can be cited. In addition, the brain function improving food of the present invention can also be used for the purpose of preventing or improving fatigue caused by the use of brain function.

[0157] As more specific subjects of the food for improving brain function of the present invention, for example, people who want the following effects can be cited: people who want to improve forgetfulness in middle-aged and elderly people, improve forgetfulness that increases with age, maintain memory that decreases with age (the ability to remember and remember actions or judgments generated in daily life), maintain attention that decreases with age (the ability to keep attention and continue an action), improve the accuracy of memory that decreases with age (recalling things that are perceived and recognized), etc. In addition, as more specific subjects of the food for improving brain function of the present invention, people who want to reduce fatigue of the head (brain), clear the head (brain), calm the heart (brain), support the activities of the head (brain), etc.

[0158] Example

[0159] Hereinafter, the present invention will be described in more detail with reference to Examples, but the present invention is not limited to these Examples.

[0160] [Test Example 1 (for reference)]

[0161] According to the dosage and usage shown in Table 1, the composition containing rifampicin or not containing rifampicin was administered to the Alzheimer's disease model mice shown in Table 1 every day for 1 month.

[0162] (Target group)

[0163] Prepare APP for 11-month-old male OSK Mouse (Tomiyama et al. J Neurosci. 2010; 30:4845-56). APP OSK The weight of the mouse is about 30 g. OSK 60 mice were divided into 5 groups of 12 AE mice each. In addition, 12 wild-type mice (non-Tg littermate) of the same age were prepared. OSK The mice were amyloid precursor protein (APP) transgenic mice (an Alzheimer's disease model) and showed accumulation of β-amyloid (Aβ) protein.

[0164] (Administration composition)

[0165] In a 0.5 w / v% sodium carboxymethylcellulose (CMC; Sigma-Aldrich, carboxymethylcellulose sodium salt, low viscosity, C5678) aqueous solution (hereinafter referred to as "CMC"), a rifampicin drug (RFP; Sigma-Aldrich, rifampicin ≥ 97% (HPLC), powder, alias: 3-(4-methylpiperazinyliminomethyl) rifamycin SV, rifamycin AMP, Rifampin, R3501) was suspended in an amount corresponding to the dosage shown in Reference Examples 1 to 4 in Table 1 to prepare a composition for administration. In addition, for Reference Examples 1 to 2, a composition for administration was prepared in the same manner as above except that the rifampicin drug was not contained.

[0166] (Dosage method)

[0167] Oral administration used an oral probe for rodents, nasal administration used PIPETMAN (white tip), and subcutaneous administration used a syringe, all of which were performed without anesthesia.

[0168] [Table 1]

[0169]

[0170] (Result 1 - Action Test (Cognitive Function))

[0171] The mice after the administration (12 months old) were subjected to behavioral tests to compare the effect of rifampicin on the cognitive function of mice. The behavioral test was conducted according to the method of Umeda et al. Brain 2016; 139: 1568-86, using the Morris water maze to measure the spatial reference memory of mice. In addition, the number of mice used in the behavioral test was 12 (Reference Example 1, Reference Example 2, Reference Example 3) and 11 (Reference Example 1, Reference Example 2, Reference Example 4), excluding the mice that died during the administration period.

[0172] The results of the action test are shown in Figure 1 APP was confirmed in all cases of oral, intranasal, and subcutaneous administration. OSK Improvement of memory impairment in mice. However, it was confirmed that if it is administered orally (Reference Example 1), the improvement effect is incomplete. In contrast, if it is administered nasally (Reference Example 2 and Reference Example 3) and subcutaneously (Reference Example 4), the improvement effect reaches the same level as that of wild-type mice. Furthermore, if it is administered nasally, even if the dosage is reduced to one-fifth (0.05 mg / day) (Reference Example 3), the improvement effect is still higher than that of oral administration (Reference Example 1).

[0173] (Result 2 - Liver dysfunction)

[0174] Blood was collected from mice after the behavioral test, and serum was separated to prepare serum samples. Liver enzymes AST (GOT) and ALT (GPT) were measured in the serum samples to compare the degree of liver dysfunction caused by rifampicin.

[0175] The results of liver enzyme measurement are shown in Table 2. OSK Compared with the mice (Reference Example 2), AST increased significantly in the mice (Reference Example 1) administered with RFP orally, suggesting liver toxicity. In contrast, in the mice administered with nasal administration (Reference Example 2 and Reference Example 3), a significant AST decrease trend was observed compared with Reference Example 1. Among them, a more significant AST decrease trend was observed in the mice administered with nasal administration at a lower dose (Reference Example 3). No increase in AST was observed in subcutaneous administration (Reference Example 4). As for ALT, no significant changes were observed by any administration method.

[0176] [Table 2]

[0177]

[0178] The values ​​of AST and ALT were expressed as Mean±SEM (IU / L).

[0179] *The p value of the inter-group difference in AST values ​​among Non-Tg mice, CMC-administered Tg mice, and subcutaneously-administered Tg mice was p<0.05 (based on Tukey-Kramer test).

[0180] Normal values ​​in C57BL6 mice were 68±24 for AST and 30±8 for ALT.

[0181] (Result 3 - Immunohistochemical staining (brain pathology))

[0182] Brains were removed from mice after the behavioral test and the effects of rifampicin on Aβ oligomers, synaptophysin, and phosphorylated Tau were compared by immunohistochemical staining.

[0183] According to the procedure described in Umeda et al, Brain 2016; 139: 1568-86, Aβ oligomers (Aβ oligomers are believed to cause phosphorylation of Tau and reduction of synaptophysin), synaptophysin (a marker protein of synapses), and phosphorylated Tau were stained by immunohistochemical staining. 11A1 antibody (manufactured by Immuno-Biological Research Institute, Ltd.) was used for staining of Aβ oligomers, SVP-38 antibody (manufactured by Sigma) was used for staining of synaptophysin, and mouse monoclonal PHF-1 antibody (anti-p-Ser396 / 404-tau antibody, provided by Dr. Peter Davies of Albert Einstein College of Medicine) was used for staining of phosphorylated Tau. After staining, Aβ oligomers, synaptophysin, and phosphorylated Tau were quantified using NIH image-J.

[0184] The photographs of tissues after immunostaining for Aβ oligomers and synaptophysin are shown in Figure 2 . Figure 2 In the figure, the upper part shows hippocampal CA3 tissue, and the lower part shows hippocampal CA2 / 3 tissue. In any case of oral administration (Reference Example 1), nasal administration (Reference Example 2, Reference Example 3), and subcutaneous administration (Reference Example 4) of RFP, Aβ oligomers accumulated in the brain decreased, and the decreased synaptophysin was restored.

[0185] Will be Figure 2 The quantitative results of Aβ oligomers obtained by immunostaining are shown in Figure 3In any case of oral administration (Reference Example 1), nasal administration (Reference Example 2, Reference Example 3), and subcutaneous administration (Reference Example 4) of RFP, Aβ oligomers were reduced to at least the same level as that of wild-type mice (Reference Example 1). Among them, when compared at the same dosage, the reduction effect caused by the removal of Aβ oligomers was the highest in nasal administration (Reference Example 2).

[0186] Will be Figure 2 The quantitative results of synaptophysin obtained by immunostaining are shown in Figure 4 . Regardless of the oral administration (Reference Example 1), nasal administration (Reference Example 2, Reference Example 3), or subcutaneous administration (Reference Example 4) of RFP, synaptophysin in the hippocampus showed a recovery trend. Among them, the effect caused by oral administration (Reference Example 1) was weak. On the other hand, if it was administered nasally (Reference Example 2, Reference Example 3) or subcutaneously (Reference Example 4), it recovered to the same level as the wild-type mice (Reference Example 1). Furthermore, similar to the results of the action test, it was confirmed that when nasally administered, even when the dosage was reduced to one-fifth (0.05 mg / day) (Reference Example 3), its effect was still higher than that of oral administration (Reference Example 1).

[0187] The photographs of tissues after immunostaining for phosphorylated tau are shown in Figure 5 . Figure 5 The hippocampal CA2 / 3 tissue was shown. In any case of oral administration (Reference Example 1), nasal administration (Reference Example 2, Reference Example 3), and subcutaneous administration (Reference Example 4) of RFP, phosphorylated Tau accumulated in the brain was reduced.

[0188] Will be Figure 5 The quantitative results of phosphorylated Tau obtained by immunostaining are shown in Figure 6 . In any case of oral administration (Reference Example 1), nasal administration (Reference Example 2, Reference Example 3), and subcutaneous administration (Reference Example 4) of RFP, phosphorylated Tau in the hippocampus showed a tendency to decrease. Among them, the effect caused by oral administration (Reference Example 1) was weak, while on the other hand, the effects caused by nasal administration (Reference Example 2, Reference Example 3) and subcutaneous administration (Reference Example 4) were high. Furthermore, if the same dosage is compared, the reduction effect caused by the removal of phosphorylated Tau is the highest in nasal administration (Reference Example 2).

[0189] The above results confirm that, in the administration of rifampicin, nasal administration is superior to oral administration in terms of high efficacy and low side effects, and is superior to subcutaneous administration in terms of non-invasiveness. In addition, the one-month administration period for mice that produced such an effect is equivalent to about 3.3 years in humans. Therefore, it is shown that nasal administration of rifampicin is suitable for long-term administration, and therefore, it is suitable not only for the treatment of dementia, but also for the prevention of dementia.

[0190] In order to extrapolate the effective dose of mice to the effective dose in the human body, the size, shape, and function of the nose, nasal mucosa, and olfactory nerve can be considered to be different and appropriately determined. In the above-mentioned reference examples, mice (body weight about 30g) are measured by nasal administration, showing the effective dose of 0.05mg / only / day (1.67mg / kg days) and 0.25mg / only / day (8.33mg / kg days). By the result obtained, even if the dosage of about one tenth of these dosages, the effect can also be expected. In addition, it is believed that it is also possible to administer more long-term, therefore, if this more long-term administration is considered, even if less dosage (such as 0.15mg / kg days) can also be expected to have an effect. On the other hand, considering that the oral dosage of rifampicin for humans is prescribed at 450 to 600 mg / 60 kg·day (7.5 to 10 mg / kg·day), and in the above-mentioned reference example, even a small amount of nasal administration of one-fifth of the oral administration is effective, it can be considered that even a dosage of 1 / 2 of the current dosage (e.g., 3.75 mg / kg·day) is effective in human administration. In summary, in human administration, 0.15 to 3.75 mg / kg·day can be set as an effective dosage. In addition, as shown in Test Example 2 described later, since nasal administration of rifampicin is suitable for the prevention or treatment of synucleinopathy, the same effective dosage can also be set for synucleinopathy.

[0191] [Test Example 2 (for reference)]

[0192] According to the dosage and usage shown in Table 3, the composition containing or not containing rifampicin was administered to the synuclein disease model mice shown in Table 3 every day for 1 month.

[0193] (Target group)

[0194] As a model of synuclein disease, α-synuclein transgenic (αSyn-Tg) mice with A53T mutation were purchased from Jackson Laboratory. The mouse has been reported as a model of Parkinson's disease showing motor dysfunction from about 9 months of age (hereinafter, also recorded as 9 months (9mo) mice of αSyn-Tg) (Lee et al. Proc Natl Acad Sci USA. 2002; 99: 8968-73). However, as described later, the results of the detailed research by the inventors of the present invention, although the mouse has normal motor function but shows cognitive dysfunction from about 6 months of age, from about 6 months of age to about 9 months of age, it can also be used as a model of Lewy body dementia (hereinafter, also recorded as 6 months (6mo) mice of αSyn-Tg) Use. Therefore, in this test example, as the subject of administration, 6 months (6mo) mice of αSyn-Tg and 9 months (9mo) mice of αSyn-Tg are used.

[0195] The motor function and cognitive function of the model mice were confirmed by the following motor function test and cognitive function test. The motor function test was performed using a rotating rod. The mice were placed on a rotor rotating at a speed of 5 rpm (5 revolutions per minute) and trained to walk on the rotor for 3 minutes. Then, they were placed on a rotor whose rotation speed was increased from 4 rpm to 40 rpm in 4 minutes, and the time (in seconds) until they fell from the rotor was measured (they were considered to have fallen when they rotated one circle in a state close to the rotor). The measurement was performed twice a day, and the average value was calculated. The cognitive function test was performed according to the method of Umeda et al. Brain 2016; 139: 1568-86 by measuring the spatial reference memory of mice in the Morris water maze (hereinafter, the same in this test example). The results of the motor function test are shown in Figure 7 The cognitive function test results are shown in Figure 8 .like Figure 7 and Figure 8 As shown in the results, it was found that 6-month-old αSyn-Tg mice had no abnormal motor function and decreased cognitive function, thus becoming a model of dementia with Lewy bodies (DLB). In addition, 9-month-old αSyn-Tg mice showed accumulation of α-synuclein, and both motor function and cognitive function were decreased as described later, thus becoming a model of Parkinson's disease (PD).

[0196] (Administration composition)

[0197] In a 0.5 w / v% sodium carboxymethylcellulose (CMC; Sigma-Aldrich, carboxymethylcellulose sodium salt, low viscosity, C5678) aqueous solution (hereinafter referred to as "CMC"), a rifampicin drug (RFP; Sigma-Aldrich, rifampicin ≥ 97% (HPLC), powder, alias: 3-(4-methylpiperazinyliminomethyl) rifamycin SV, rifamycin AMP, Rifampin, R3501) was suspended in an amount to give the dosage shown in Reference Examples 5 to 6 in Table 3 to prepare a composition for administration. In addition, for Reference Examples 4 to 5, a composition for administration was prepared in the same manner as above except that the rifampicin drug was not contained.

[0198] (Dosage method)

[0199] In the same manner as in Test Example 1, nasal administration was performed.

[0200] [Table 3]

[0201]

[0202] (Result 1 - Action Test (Cognitive Function))

[0203] αSyn-Tg mice before (6 months) and after (7 months) administration were subjected to Morris water maze behavioral tests to compare the effects of rifampicin on the cognitive function of mice. The results of the behavioral tests are shown in Fig. 9 . Before administration, memory impairment was observed in αSyn-Tg mice (Reference Example 5, Reference Example 5), but in αSyn-Tg mice (Reference Example 5) to which rifampicin was administered nasally, improvement in memory impairment was seen from the first day after administration, and on the fourth day after administration, cognitive function recovered to the same level as normal Non-Tg mice (Reference Example 4). That is, it is shown that the effect of rifampicin in removing α-synuclein is so high that cognitive function is improved to a normal level. In addition, as in Test Example 1, since Reference Example 5 is a nasal administration of rifampicin, the side effects on liver dysfunction are also significantly reduced. Furthermore, in Reference Example 5, the dosage of rifampicin is a low dosage of 0.1 mg / day / mouse, so the side effects on liver dysfunction are also more significantly reduced.

[0204] (Result 2 - Western Blot (Brain Pathology))

[0205] Brains were removed from αSyn-Tg 9-month-old mice and the effect of rifampicin on α-synuclein oligomers was compared by Western blotting.

[0206] The weight of the brain was measured, and 5 times the amount (considered as 1 g = 1 mL) of buffer A (Masuda-Suzukake et al. Acta Neuropathol Commun. 2014; 2: 88) was added, and a homogenate was prepared by sonication. The homogenate was centrifuged at 100,000 g and 4°C for 30 minutes. The centrifugal supernatant was recovered, and an equal amount of 2×SDS sample buffer was added, and boiled for 5 minutes. The obtained sample was electrophoresed in a 12% acrylamide gel and transferred to an Immobilon-P membrane (Merck Millipore, IPVH304F0). After reacting anti-α-synuclein antibody (Santa Cruz Biotechnology, sc-58480) and HRP (horseradish peroxidase)-anti-mouse IgG antibody (Bio-Rad Laboratories, 170-6516), ImmunoStar LD (Wako Pure Chemical Industries, Ltd., 290-69904) was added as a matrix, and the α-synuclein band was visualized using ImageQuant LAS 500 (GE Healthcare Japan). The band was quantified using Multi Gauge Ver2.0 (Fuji Film).

[0207] The results of Western blotting are shown in Fig.10 .like Fig.10 As shown, in αSyn-Tg mice (Reference Example 7), α-synuclein oligomers were observed, which were not observed in normal Non-Tg mice (Reference Example 6), but in αSyn-Tg mice (Reference Example 5) to which rifampicin was intranasally administered, a decrease in α-synuclein oligomers was observed. Fig.10 The quantitative results of α-synuclein obtained by Western blotting are shown in Fig.11 .like Fig.11 As shown, the α-synuclein oligomers in αSyn-Tg mice (Reference Example 5) to which rifampicin was intranasally administered were significantly reduced compared with those in αSyn-Tg mice before administration (Reference Example 7).

[0208] [Test Example 3: Nasal administration of the first pharmaceutical product to Alzheimer's disease model mice]

[0209] According to the dosage and usage shown in Table 4, the Alzheimer's disease model mice shown in Table 4 were administered daily with a composition containing rifampicin (RFP) alone, a composition containing resveratrol (Res) alone, a composition containing rifampicin and resveratrol, and a composition containing neither rifampicin nor resveratrol for 1 month.

[0210] (Target group)

[0211] The same APP as in Test Example 1 OSK Mice were used as drug administration subjects.

[0212] (Administration composition)

[0213] In a 0.5 w / v% sodium carboxymethylcellulose (CMC; Sigma-Aldrich, carboxymethylcellulose sodium salt, low viscosity, C5678) aqueous solution (hereinafter referred to as "CMC"), a rifampicin drug (RFP; Sigma-Aldrich, rifampicin ≥ 97% (HPLC), powder, alias: 3-(4-methylpiperazinyl iminomethyl) rifamycin SV, rifamycin AMP, Rifampin, R3501) and / or resveratrol (Res; Fujifilm Wako Pure Chemical Industries, Ltd., ≥ 98% (HPLC), alias: 3,5,4′-trihydroxy-trans-stilbene) was suspended in an amount corresponding to the dosage shown in Reference Example 10, Comparative Example 1, and Example 1 in Table 4 to prepare a composition for administration. In addition, for Reference Examples 8 to 9, a composition for administration was prepared in the same manner as above except that none of the rifampicin drug and resveratrol was contained.

[0214] (Dosage method)

[0215] In the same manner as in Test Example 1, nasal administration was performed.

[0216] [Table 4]

[0217]

[0218] (Result 1 - Action Test (Cognitive Function))

[0219] The Morris water maze test was performed on the mice of Reference Examples 8 to 11, Comparative Example 1, and Example 1 in the same manner as in Test Example 1. The results are shown in Fig.12 Compared with APP without rifampicin OSK Mice (Reference Example 9) were given 0.02 mg of rifampicin in APP OSK In mice (Comparative Example 1), a tendency of improvement in cognitive function was observed. OSK Mice (Reference Example 9) were given APP with 0.02 mg of resveratrol. OSK In mice (Reference Example 10), a tendency of improvement in cognitive function was also observed. OSKIn the mice (Example 1), cognitive function was significantly improved, and the degree of improvement reached the same degree as that of normal Non-Tg mice (Reference Example 8). That is, there was no significant difference in cognitive function in the cases where rifampicin and resveratrol were administered alone (Comparative Example 1, Reference Example 10). In view of this, the cognitive function improvement effect obtained by combining rifampicin and resveratrol (Example 1) exceeded the sum of the effects caused by the individual administration of rifampicin and resveratrol (Comparative Example 1, Reference Example 10), and was a significant effect beyond the expected degree.

[0220] (Result 2 - Immunohistochemical staining (brain pathology))

[0221] The same operation as in Experimental Example 1 was performed to compare the effect of rifampicin on Aβ oligomers by immunohistochemical staining. The results are shown in Fig.13 In addition, Fig.13 The results of the graphing of the staining intensity in (a) are shown in Fig.13 As shown in these results, in normal Non-Tg mice (Reference Example 8), no Aβ oligomer accumulation was observed, but in APP mice not given rifampicin, OSK In mice (Reference Example 9), accumulation of Aβ oligomers was observed. OSK Mice (Comparative Example 1) and APP administered with 0.02 mg of resveratrol OSK In all cases of mice (Reference Example 10), the effect of removing accumulated Aβ oligomers was observed, but the extent was not as great as that of Example 1 described later. OSK In mice (Example 1), it was shown that the accumulated Aβ oligomers were sufficiently removed.

[0222] (Result 3 - Liver dysfunction)

[0223] The same operation as in Test Example 1 was carried out to compare the degree of liver dysfunction caused by rifampicin based on the measurement results of AST for the mice of Reference Examples 8 to 10, Comparative Example 1 and Example 1. The results are shown in Fig.14 .

[0224] like Fig.14 As shown, the normal Non-Tg mice (Reference Example 8) and APP mice not given rifampicin OSK In mice (Reference Example 9), no increase in AST, which indicates a side effect due to liver dysfunction, was observed. In contrast, although not shown in the figure, it was confirmed that APP administered with 0.1 mg of resveratrol alone OSK APP in mice compared to those without rifampicin administration OSKIn mice (Reference Example 9), AST decreased, and a positive liver protective effect was observed. On the other hand, APP was administered with 0.02 mg of resveratrol alone. OSK The AST of mice (Reference Example 10) did not decrease because the amount of resveratrol was too small.

[0225] In addition, if Fig.14 As shown, in the case of APP with rifampicin 0.02 mg alone OSK In mice (Comparative Example 1), an increase in AST was observed, which indicates a side effect. The increase in AST in Comparative Example 1 was significantly lower than that in the oral administration as shown in the above-mentioned Test Example 1, and was also further reduced compared to the reference example 3 in which 0.05 mg was administered. However, in the APP in which resveratrol and rifampicin were administered in combination, OSK In mice (Example 1), AST was reduced to APP levels comparable to those of mice not given rifampicin. OSK In Example 1, although the dosage of resveratrol combined with rifampicin was the same low dosage as in Reference Example 10, where resveratrol alone did not show an effective liver protective effect (in fact, Fig.14 In the case of AST, even in comparison with Reference Example 9, AST did not decrease in Reference Example 10, but an effective liver protective effect was observed by combining with rifampicin. In addition, although not shown in the figure, when APP was administered alone with 0.1 mg of resveratrol, which has been confirmed to have a positive liver protective effect, OSK In mice, AST is about 86 IU / L. The degree of reduction in the amount of AST in Example 1 relative to the amount of AST in Comparative Example 1 (i.e., the liver protective effect caused by the combined 0.02 mg of resveratrol) is not inferior to the degree of reduction in the amount of AST in 0.1 mg of resveratrol relative to the amount of AST in Reference Example 9 (i.e., the liver protective effect caused by 0.1 mg of resveratrol alone), and in view of this, the side effect reduction effect caused by resveratrol combined with rifampicin can be said to be very significant.

[0226] [Test Example 4: Nasal administration of the first pharmaceutical product to synucleinopathy model mice]

[0227] According to the dosage and usage shown in Table 5, the synuclein disease model mice shown in Table 5 were administered with the administration composition containing rifampicin and resveratrol or not containing rifampicin and resveratrol every day for 1 month.

[0228] (Target group)

[0229] Seven-month-old (7mo) synucleinopathy model mice ([A53T]αSyn-Tg) described in Test Example 2 were used as administration subjects. This mouse is a dementia with Lewy bodies (DLB) model in which there is no abnormality in motor function but reduced cognitive function.

[0230] (Administration composition)

[0231] In a 0.5 w / v% aqueous solution of sodium carboxymethylcellulose (CMC; Sigma-Aldrich, sodium carboxymethylcellulose, low viscosity, C5678), a rifampicin drug (RFP; Sigma-Aldrich, rifampicin ≥97% (HPLC), powder, alias: 3-(4-methylpiperazinyl iminomethyl) rifamycin SV, rifamycin AMP, Rifampin, R3501) and resveratrol (Res; Fujifilm Wako Pure Chemical Industries, Ltd., ≥98% (HPLC), alias: 3,5,4′-trihydroxy-trans-stilbene) were suspended in amounts to give the dosages shown in Examples 2 and 3 of Table 5 to prepare a composition for administration. In addition, for Reference Examples 11 and 12, a composition for administration was prepared in the same manner as above except that neither the rifampicin drug nor the resveratrol was contained.

[0232] (Dosage method)

[0233] In the same manner as in Test Example 1, nasal administration was performed.

[0234] [Table 5]

[0235]

[0236] (Results - Action Test (Cognitive Function))

[0237] The Morris water maze test was performed on the mice of Reference Examples 11 and 12 and Examples 1 and 2 in the same manner as in Test Example 1. The results are shown in Fig.15 In the synuclein disease model mice (reference example 12) not administered with the mixture of rifampicin and resveratrol, there was only a slight tendency of improvement in cognitive function. In contrast, in the synuclein disease model mice (examples 2 and 3) administered with the mixture of rifampicin and resveratrol, a significant tendency of improvement in cognitive function was observed, and the improvement in cognitive function was observed to be close to that of wild-type mice (reference example 11). Furthermore, the effect of improving cognitive function caused by the mixture of rifampicin and resveratrol can be confirmed to be dosage-dependent, as seen in the comparison between example 2 and example 3.

[0238] [Test Example 5: Nasal Administration of the First Pharmaceutical Product to Tauopathy Model Mice]

[0239] According to the dosage and usage shown in Table 6, the composition containing rifampicin and resveratrol or not containing rifampicin and resveratrol was administered to the Tau protein disease model mice shown in Table 6 every day for 1 month.

[0240] (Target group)

[0241] Tauopathy model mice were prepared (Umeda T et al., Am. J. Pathol. 183, 211-225, 2013), and 14-15 month old (14-15 mo) model mice were used as administration subjects.

[0242] (Administration composition)

[0243] In a 0.5 w / v% sodium carboxymethylcellulose (CMC; Sigma-Aldrich, sodium carboxymethylcellulose, low viscosity, C5678) aqueous solution, a rifampicin drug (RFP; Sigma-Aldrich, rifampicin ≥ 97% (HPLC), powder, alias: 3-(4-methylpiperazinyl iminomethyl) rifamycin SV, rifamycin AMP, Rifampin, R3501) and / or resveratrol (Res; Fujifilm Wako Pure Chemical Industries, Ltd., ≥ 98% (HPLC), alias: 3,5,4′-trihydroxy-trans-stilbene) was suspended in an amount corresponding to the dosage shown in Comparative Example 2, Reference Example 15, Example 4, and Example 5 in Table 6 to prepare a composition for administration. In addition, for Reference Examples 13 to 14, a composition for administration was prepared in the same manner as above except that neither the rifampicin drug nor the resveratrol was contained.

[0244] [Table 6]

[0245]

[0246] (Results - Action Test (Cognitive Function))

[0247] The Morris water maze test was performed on the mice of Reference Examples 13 to 15, Comparative Example 2, and Examples 4 to 5 in the same manner as in Test Example 1. The results are shown in FIG. Fig.16In the Tau disease model mice (Reference Example 14) that were neither administered with rifampicin nor with resveratrol, there was only a slight tendency for improvement in cognitive function, and the Tau disease model mice (Comparative Example 2 and Reference Example 15) that were administered with a single dose of rifampicin or a single dose of resveratrol had a slow effect on improving cognitive function. In contrast, in the Tau disease model mice (Examples 4 and 5) that were administered with a mixture of rifampicin and resveratrol, a significant tendency for improvement in cognitive function was observed, and improvement in cognitive function was observed to the extent that was no different from that of wild-type mice (Reference Example 13). In addition, in Example 5 in which the total amount of rifampicin and resveratrol is 0.02 mg, compared with Comparative Example 2 or Reference Example 15 in which 0.02 mg of each of rifampicin and resveratrol were administered alone, a significant improvement in cognitive function was obtained. Therefore, the cognitive function improvement effect obtained by combining rifampicin and resveratrol (Example 5) exceeds the sum of the effects caused by the individual administration of rifampicin and resveratrol (Comparative Example 2, Reference Example 15), and can be said to be a significant effect that exceeds the expected level.

[0248] [Test Example 6: Nasal administration of the second pharmaceutical product to Alzheimer's disease model mice]

[0249] like Fig.12 Reference Example 10 and Fig.16 As shown in Reference Example 15, when mice were given 0.02 mg of resveratrol alone for 1 month, a slow improvement in cognitive function was achieved for neurodegenerative diseases. This slow but effective effect was confirmed by the following method: Fig.13 (a) and Fig.13 As shown in Reference Example 10 of (b), the effect of removing accumulated Aβ oligomers was also observed when 0.02 mg of resveratrol was administered to mice alone for 1 month. In this test example, it was further verified that the administration of resveratrol to the Alzheimer's disease model at a dosage of 0.1 mg was also effective. Specifically, the results of daily administration of a composition containing resveratrol alone or not containing resveratrol to the Alzheimer's disease model mice shown in Table 7 for 1 month according to the dosage and usage shown in Table 7 are shown.

[0250] (Target group)

[0251] The APP of 13 months old (13mo) described in Test Example 1 was used OSK Mouse.

[0252] (Administration composition)

[0253] Resveratrol (Res; Fujifilm Wako Pure Chemical Industries, Ltd., ≥98% (HPLC), alias: 3,5,4′-trihydroxy-trans-stilbene) was suspended in a 0.5 w / v% aqueous solution of sodium carboxymethylcellulose (CMC; Sigma-Aldrich, sodium carboxymethylcellulose, low viscosity, C5678) in an amount as shown in Examples 6 and 7 in Table 7 to prepare a composition for administration. In addition, for Reference Examples 16 and 17, compositions for administration were prepared in the same manner as above except that resveratrol was not contained.

[0254] (Dosage method)

[0255] In the same manner as in Test Example 1, nasal administration was performed.

[0256] [Table 7]

[0257]

[0258] (Results - Action Test (Cognitive Function))

[0259] The Morris water maze test was performed on the mice of Reference Examples 16 and 17 and Examples 6 and 7 in the same manner as in Test Example 1. The results are shown in Fig.17 . Compared with the improvement effect of cognitive function in Alzheimer's disease model mice not administered with resveratrol (reference example 17), the improvement effect of cognitive function was observed in Alzheimer's disease model mice administered with resveratrol (Examples 6 and 7). Among them, as shown in Example 7, when resveratrol was administered at a dose of 0.1 mg / day (Example 7), the improvement of cognitive function was observed to be close to that of wild-type mice (reference example 16), but even when resveratrol was administered at a dose of 0.02 mg / day (Example 6), although it was slow, the improvement effect of cognitive function was observed.

[0260] The mice used in this test example are models that were created in which the cognitive function is impaired due to the accumulation of Aβ oligomers. Fig.13 (a) and Fig.13 As shown in Reference Example 10 of (b), when 0.02 mg of resveratrol was administered alone to the model mice for 1 month, pathological results such as the significant removal of accumulated Aβ oligomers were observed. In view of the above, it is clear that the cognitive function can be improved by administering 0.02 mg of resveratrol. Therefore, according to the n=10 mice used in this test example, although the cognitive function improvement effect caused by 0.02 mg of resveratrol is as follows Fig.17 As shown, in terms of mechanism, it is clear that the cognitive function improvement effect can be observed with the significance observed in the mice of Example 7.

[0261] [in conclusion]

[0262] As shown in the above examples, first, according to the results of administering a mixture of rifampicin and resveratrol to Alzheimer's disease models, synuclein disease model mice, and Tau protein disease model mice, it was confirmed that the mixture of rifampicin and resveratrol can reduce side effects and is effective for neurodegenerative diseases at low doses, thereby suggesting that long-term administration is possible; second, according to the results of administering a single dose of resveratrol to the Alzheimer's disease model, it was confirmed that the mixture of resveratrol is effective for neurodegenerative diseases at low doses, thereby suggesting that long-term administration and long-term intake are possible. In fact, as shown in the above examples, continuous administration can be performed on mice over a long period of 1 month.

[0263] In order to extrapolate the effective amount in mice to the effective amount in the human body, the difference in size, shape, and function of the nose, nasal mucosa, and olfactory nerve can be appropriately determined. In the above-mentioned embodiment related to the first pharmaceutical product, as the dosage of rifampicin to mice (body weight of about 30g), the effect caused by a lower dosage such as 0.02mg / mouse / day (0.66mg / kg·day) or 0.01mg / mouse / day (0.33mg / kg·day) is shown. According to the results obtained, even if the dosage is about one-tenth of these dosages, of course, the effect can be expected. In addition, it is believed that longer-term administration is also possible. Therefore, if this further long-term administration is considered, even a smaller dosage (for example, 0.001mg / kg·day) can also be expected to have an effect. On the other hand, the oral dosage of rifampicin for humans is prescribed at 450 to 600 mg / 60 kg·day (7.5 to 10 mg / kg·day). In the above-mentioned reference example, the nasal administration shows an effect even with a small amount of 1 / 12.5 of the oral administration (reference example 1 of test example 1). In view of the above, it can be considered that even 1 / 5 of the dosage so far (for example, 1.5 mg / kg·day) is effective in human administration. In summary, 0.001 to 1.5 mg / kg·day can also be set as the dosage in human administration. If it is summarized as the dosage of 0.15 to 3.75 mg / kg·day derived in test example 1, 0.001 to 3.75 mg / kg·day can be set as the dosage in human administration.

[0264] In the embodiment related to the first pharmaceutical product described above, the composition for nasal administration is prepared in such a way that rifampicin and resveratrol are equal in amount, and therefore, the dosage of resveratrol to humans can also be the same as the dosage of rifampicin to humans derived above. It should be noted that even if the dosage of resveratrol is lower than the dosage of 0.1 mg / mouse / day (3.3 mg / kg·day) at which resveratrol alone shows a positive liver protective effect, or the dosage of 0.02 mg / mouse / day (0.66 mg / kg·day) or 0.01 mg / mouse / day (0.33 mg / kg·day) at which resveratrol alone does not show an effective liver protective effect, a significant side effect reduction effect can be obtained by combining with rifampicin. In view of this, the dosage of resveratrol to humans can also be set to a smaller dosage of 0.001 to 2.5 mg / kg·day.

[0265] In addition, in order to extrapolate the effective amount in mice to the effective amount in the human body, more specifically, it can also be derived based on the human equivalent dosage disclosed in FDA Guidance Document UCM078932. For example, when converting the human equivalent dosage based on the body surface area of ​​mice, a divisor such as 12.3 is used. Specifically, by dividing the dosage (mg / kg) of mice weighing 30g by 12.3, the dosage (mg / kg) of a person weighing 60kg can be derived. Accordingly, if the dosage of 0.02mg / mouse / day (0.66mg / kg·day) or 0.01mg / mouse / day (0.33mg / kg·day) of rifampicin and resveratrol used in the embodiment related to the first pharmaceutical product is converted to humans, it becomes 0.054mg / kg·day or 0.027mg / kg·day, respectively. In addition, when the dosage of 0.02 mg / mouse / day (0.66 mg / kg·day) or 0.1 mg / mouse / day (3.3 mg / kg·day) of resveratrol used in the examples related to the second pharmaceutical product is converted to 0.054 mg / kg·day or 0.27 mg / kg·day for humans, respectively.

[0266] Furthermore, in the above-mentioned embodiment, by preparing a composition for nasal administration with a sodium carboxymethylcellulose aqueous solution as a solvent and a ratio of 1 part by weight of resveratrol to 1 part by weight of rifampicin, sufficient effectiveness in mice is shown. As described above, in order to extrapolate the effective amount in mice to the effective amount in the human body, it can be appropriately determined considering the differences in size, shape, function, etc. of the nose, nasal mucosa, olfactory nerve, etc. Furthermore, in order to make the composition for nasal administration easy to absorb the drug through the nasal mucosa, it is hoped that the composition for nasal administration will be retained in the absorption site in the nasal cavity for a long time. Therefore, the following tendency can also be considered at the same time: the lower the solubility of the component in water, the easier it is to be affected by the movement of the mucus layer caused by ciliated cells in the nasal cavity and flow to the digestive tract. The solubility of rifampicin in water is 2.5 mg / mL at 25°C, and the solubility of resveratrol in water is 0.03 mg / mL at 25°C. When the difference in solubility in water further increases the effect of the difference in the ease of the drug flowing from the nasal cavity to the digestive tract in the human body, the content of resveratrols per 1 weight part of rifampicin can be 1 to 500 weight parts. On the contrary, when the difference in solubility in water further decreases the effect of the difference in the ease of the drug flowing from the nasal cavity to the digestive tract in the human body, the content of resveratrols per 1 weight part of rifampicin can be 1 / 500 to 1 weight part. To summarize the above, the content of resveratrols per 1 weight part of rifampicin can be set to 1 / 500 to 500 weight parts.

[0267] In addition, in the above-mentioned embodiment, the effect on neurodegenerative diseases was confirmed by administering the first and second drugs to mice for 1 month. Here, the life span of mice is generally about 2 to about 2.2 years. For example, in "Induction of prolonged natural lifespans in mice exposed to acoustic environmental enrichment" 2018, Scientific Reports volume 8, Article number: 7909, Yuichi Yamashita et al., C57BL / 6J rats (4 males and 4 females) were raised in a common experimental animal breeding environment, and the results showed that the average life span was about 700 days (about 2 years). On the other hand, according to WORLD HEALTH STATISTICS OVERVIEW 2019 MONITORING HEALTH FOR THE SDGs by the World Health Organization, it is shown that the life span of people in high-income countries is about 80 years old. Thus, by comparing the life span of experimental mice with that of humans, about 36 to about 40 times the life span of experimental mice is equivalent to the life span of humans, and therefore, one month (31 days) of administration to experimental mice is equivalent to about 3 years or more of administration to humans. Therefore, the administration period when the first and second pharmaceuticals are administered to humans can be preferably set to 2.5 years or more, more preferably 2.8 years or more, and more preferably 3 years or more.

Claims

1. A preventive or therapeutic drug for neurodegenerative diseases, which is a combination of rifampicins and resveratrol, wherein the rifampicins are selected from the group consisting of rifampicin and its salts, The resveratrol is contained in an amount of 0.5 to 2 parts by weight relative to 1 part by weight of the rifampicin. The preventive or therapeutic drug is used for nasal administration, The neurodegenerative disease is Alzheimer's disease, synucleinopathy or Tauopathy.

2. The preventive or therapeutic drug according to claim 1, wherein The dosage of the rifampicin is 3.75 mg / kg·day or less.

3. The preventive or therapeutic drug according to claim 1, wherein The dosage of the rifampicin is 0.001 to 1.5 mg / kg·day.

4. The preventive or therapeutic drug according to claim 1, wherein The dosage of resveratrol is 3.75 mg / kg·day or less.

5. The preventive or therapeutic drug according to claim 1, wherein The dosage of resveratrol is 0.001 to 2.5 mg / kg·day.

6. The preventive or therapeutic drug according to claim 1, wherein The preventive or therapeutic drug is a combination of the rifampicins and resveratrol.

7. The preventive or therapeutic drug according to claim 1, wherein The preventive or therapeutic drug is a kit containing a drug containing the rifampicins and a drug containing resveratrol.

Citation Information

Patent Citations

  • Cutting tool.

    EP0007909A1

  • Nasal administration of curcumin in a helium gas bolus to treat Alzheimer's disease

    JP2010524959A

  • Special compositions for use as medicines

    JP2013518034A

  • Methods and compositions for treatment of neurological disorders

    US20110111014A1

  • Compositions and methods for the treatment of altered alpha-synuclein function

    US20120052053A1